Johnson & Johnson (JNJ) 10-Q 23 Oct 20 2020 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 27, 2020	Oct. 19, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 27, 2020
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,632,542,672
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-03
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ22
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Current assets:
Cash and cash equivalents	$ 18,965	$ 17,305
Marketable securities	11,816	1,982
Accounts receivable, trade, less allowances for doubtful accounts and credit losses $292 (2019, $226)	14,579	14,481
Inventories (Note 2)	9,599	9,020
Prepaid expenses and other	2,528	2,392
Assets held for sale (Note 10)	91	94
Total current assets	57,578	45,274
Property, plant and equipment at cost	45,162	43,332
Less: accumulated depreciation	(27,307)	(25,674)
Property, plant and equipment, net	17,855	17,658
Intangible assets, net (Note 3)	47,006	47,643
Goodwill (Note 3)	34,307	33,639
Deferred taxes on income (Note 5)	7,816	7,819
Other assets	6,131	5,695
Total assets	170,693	157,728
Current liabilities:
Loans and notes payable	5,078	1,202
Accounts payable	7,044	8,544
Accrued liabilities	9,629	9,715
Accrued rebates, returns and promotions	12,418	10,883
Accrued compensation and employee related obligations	3,012	3,354
Accrued taxes on income (Note 5)	1,666	2,266
Total current liabilities	38,847	35,964
Long-term debt (Note 4)	32,680	26,494
Deferred taxes on income (Note 5)	5,615	5,958
Employee related obligations (Note 6)	10,184	10,663
Long-term taxes payable (Note 5)	6,745	7,444
Other liabilities	12,149	11,734
Total liabilities	106,220	98,257
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(14,938)	(15,891)
Retained earnings	114,831	110,659
Less: common stock held in treasury, at cost (487,676,000 and 487,336,000 shares)	38,540	38,417
Total shareholders’ equity	64,473	59,471
Total liabilities and shareholders' equity	$ 170,693	$ 157,728
Common Stock, Par or Stated Value Per Share	$ 1	$ 1
Common Stock, Shares Authorized	4,320,000,000	4,320,000,000
Common Stock, Shares, Issued	3,119,843,000	3,119,843,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Current assets:
Allowances for doubtful accounts	$ 292	$ 226
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	487,676,000	487,336,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Income Statement [Abstract]
Sales to customers	$ 21,082	$ 20,729	$ 60,109	$ 61,312
Sales to customers percent to sales	100.00%	100.00%	100.00%	100.00%
Cost of products sold	$ 6,972	$ 6,867	$ 20,613	$ 20,422
Cost of products sold percent to sales	33.10%	33.10%	34.30%	33.30%
Gross profit	$ 14,110	$ 13,862	$ 39,496	$ 40,890
Gross profit percent to sales	66.90%	66.90%	65.70%	66.70%
Selling, marketing and administrative expenses	$ 5,431	$ 5,374	$ 15,627	$ 16,139
Selling marketing and administrative expenses percent to sales	25.80%	26.00%	26.00%	26.30%
Research and development expense	$ 2,840	$ 2,599	$ 8,127	$ 8,123
Research and development expense percent to sales	13.50%	12.50%	13.50%	13.30%
In-process research and development	$ 138	$ 0	$ 144	$ 890
In-process research and development percent to sales	0.60%	0.00%	0.30%	1.40%
Interest income	$ (12)	$ (89)	$ (98)	$ (276)
Interest income percent to sales	(0.10%)	(0.40%)	(0.20%)	(0.50%)
Interest expense, net of portion capitalized	$ 44	$ 48	$ 114	$ 233
Interest expense, net of portion capitalized percent to sales	0.20%	0.20%	0.20%	0.40%
Other (income) expense, net	$ 1,200	$ 4,214	$ 545	$ 2,509
Other (income) expense, net percent to sales	5.70%	20.30%	0.90%	4.10%
Restructuring (Note 12)	$ 68	$ 69	$ 187	$ 162
Restructuring charge percent to sales	0.30%	0.40%	0.30%	0.30%
Earnings before provision for taxes on income	$ 4,401	$ 1,647	$ 14,850	$ 13,110
Earnings before provision for taxes on income percent to sales	20.90%	7.90%	24.70%	21.40%
Provision for taxes on income	$ 847	$ (106)	$ 1,874	$ 2,001
Provision for (benefit from) taxes on income (Note 5)	4.00%	(0.60%)	3.10%	3.30%
NET EARNINGS	$ 3,554	$ 1,753	$ 12,976	$ 11,109
Net earnings percent to sales	16.90%	8.50%	21.60%	18.10%
NET EARNINGS PER SHARE
Basic (per share)	$ 1.35	$ 0.67	$ 4.93	$ 4.19
Diluted (per share)	$ 1.33	$ 0.66	$ 4.86	$ 4.13
AVG. SHARES OUTSTANDING
Basic (shares)	2,632,500	2,635,200	2,633,000	2,649,500
Diluted (shares)	2,669,300	2,669,900	2,670,800	2,688,100
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000	19,000	17,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 3,554	$ 1,753	$ 12,976	$ 11,109
Other comprehensive income (loss), net of tax
Foreign currency translation	222	(667)	(741)	(575)
Securities:
Unrealized holding gain (loss) arising during period	1	0	1	1
Reclassifications to earnings	0	0	0	0
Net change	1	0	1	1
Employee benefit plans:
Prior service cost amortization during period	(6)	(6)	(17)	(18)
Gain (loss) amortization during period	203	142	604	460
Net change	197	136	587	442
Derivatives & hedges:
Unrealized gain (loss) arising during period	199	1,922	1,052	1,706
Reclassifications to earnings	(24)	(1,955)	54	(1,885)
Net change	175	(33)	1,106	(179)
Other comprehensive income (loss)	595	(564)	953	(311)
Comprehensive income	4,149	1,189	13,929	10,798
Foreign Currency Translation	139	(94)	207	(50)
Employee Benefit Plans	56	34	167	69
Derivatives & Hedges	$ 47	$ (9)	$ 293	$ (48)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	MEDICAL DEVICES	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 30, 2018	$ 59,752		$ 106,216	$ (15,222)	$ 3,120	$ (34,362)
Net earnings	11,109		11,109
Cash dividends paid	(7,417)		(7,417)
Employee compensation and stock option plans	1,397		(666)			2,063
Repurchase of common stock	(6,320)					(6,320)
Other comprehensive income (loss), net of tax	(311)			(311)
Ending Balance at Sep. 29, 2019	58,210		109,242	(15,533)	3,120	(38,619)
Restructuring (Note 12)	162	$ 200
Beginning Balance at Jun. 30, 2019	60,785		109,809	(14,969)	3,120	(37,175)
Net earnings	1,753		1,753
Cash dividends paid	(2,499)		(2,499)
Employee compensation and stock option plans	363		179			184
Repurchase of common stock	(1,628)					(1,628)
Other comprehensive income (loss), net of tax	(564)			(564)
Ending Balance at Sep. 29, 2019	58,210		109,242	(15,533)	3,120	(38,619)
Restructuring (Note 12)	69	100
Beginning Balance at Dec. 29, 2019	59,471		110,659	(15,891)	3,120	(38,417)
Net earnings	12,976		12,976
Cash dividends paid	(7,823)		(7,823)
Employee compensation and stock option plans	1,866		(911)			2,777
Repurchase of common stock	(2,900)					(2,900)
Other	(70)		(70)
Other comprehensive income (loss), net of tax	953			953
Ending Balance at Sep. 27, 2020	64,473		114,831	(14,938)	3,120	(38,540)
Restructuring (Note 12)	187	200
Beginning Balance at Jun. 28, 2020	62,978		113,898	(15,533)	3,120	(38,507)
Net earnings	3,554		3,554
Cash dividends paid	(2,659)		(2,659)
Employee compensation and stock option plans	559		109			450
Repurchase of common stock	(483)					(483)
Other	(71)		(71)
Other comprehensive income (loss), net of tax	595			595
Ending Balance at Sep. 27, 2020	64,473		$ 114,831	$ (14,938)	$ 3,120	$ (38,540)
Restructuring (Note 12)	$ 68	$ 100

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 1.01	$ 0.95	$ 2.97	$ 2.80

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 12,976	$ 11,109
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	5,291	5,193
Stock based compensation	845	817
Asset write-downs	198	1,019
Contingent consideration reversal	(1,148)	0
Net gain on sale of assets/businesses	(60)	(2,125)
Deferred tax provision	(238)	(2,126)
Credit losses and accounts receivable allowances	74	(15)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(440)	(665)
Increase in inventories	(784)	(424)
(Decrease)/Increase in accounts payable and accrued liabilities	(119)	2,273
Increase in other current and non-current assets	(1,983)	(81)
Increase in other current and non-current liabilities	581	2,043
NET CASH FLOWS FROM OPERATING ACTIVITIES	15,193	17,018
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,024)	(2,238)
Proceeds from the disposal of assets/businesses, net	100	3,103
Acquisitions, net of cash acquired	(949)	(5,562)
Purchases of investments	(16,243)	(2,684)
Sales of investments	6,585	2,459
Proceeds from credit support agreements, net	125	0
Other (primarily licenses and milestones)	(516)	72
NET CASH USED BY INVESTING ACTIVITIES	(12,922)	(4,850)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(7,823)	(7,417)
Repurchase of common stock	(2,900)	(6,320)
Proceeds from short-term debt	3,335	148
Repayment of short-term debt	(310)	(87)
Proceeds from long-term debt, net of issuance costs	7,431	1
Repayment of long-term debt	(562)	(1,008)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	922	580
Other	(569)	160
NET CASH USED BY FINANCING ACTIVITIES	(476)	(13,943)
Effect of exchange rate changes on cash and cash equivalents	(135)	(83)
Increase/(Decrease) in cash and cash equivalents	1,660	(1,858)
Cash and Cash equivalents, beginning of period	17,305	18,107
Cash and Cash equivalents, end of period	18,965	16,249
Acquisitions
Fair value of assets acquired	1,173	6,861
Fair value of liabilities assumed and noncontrolling interests	(224)	(1,299)
Net cash paid for acquisitions	949	$ 5,562
Auris Health
Adjustments to reconcile net earnings to cash flows from operating activities:
Contingent consideration reversal	$ (1,148)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 27, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of September 27, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended September 27, 2020, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There were no new material accounting standards issued in the fiscal third quarter of 2020 that impacted the Company. Recently Adopted Accounting Standards There were no new accounting standards adopted in the fiscal third quarter of 2020. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Inventories

Inventories	9 Months Ended
	Sep. 27, 2020
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) September 27, 2020 December 29, 2019 Raw materials and supplies $ 1,363 1,117 Goods in process 1,916 1,832 Finished goods 6,320 6,071 Total inventories (1) $ 9,599 9,020 (1) See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 27, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2019. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) September 27, 2020 December 29, 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 38,381 36,634 Less accumulated amortization 16,098 13,154 Patents and trademarks — net 22,283 23,480 Customer relationships and other intangibles — gross 22,455 22,056 Less accumulated amortization 10,427 9,462 Customer relationships and other intangibles — net* 12,028 12,594 Intangible assets with indefinite lives: Trademarks 6,995 6,922 Purchased in-process research and development (1) 5,700 4,647 Total intangible assets with indefinite lives 12,695 11,569 Total intangible assets — net $ 47,006 47,643 *The majority is comprised of customer relationships (1) In the fiscal first quarter of 2020, the Company completed the acquisition of bermekimab and certain related assets from XBiotech Inc., as well as the acquisition of all outstanding shares in Verb Surgical Inc. and recorded in-process research and development intangible assets of $0.8 billion and $0.4 billion, respectively. Goodwill as of September 27, 2020 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1 183 184 Currency translation/Other 171 280 33 484 Goodwill at September 27, 2020 $ 9,907 9,450 14,950 34,307 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.2 billion and $1.1 billion for the fiscal third quarters ended September 27, 2020 and September 29, 2019, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $3.4 billion and $3.3 billion for the fiscal nine months ended September 27, 2020 and September 29, 2019, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 3,900 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 27, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of September 27, 2020, the total amount of cash collateral held by the Company under the CSA amounted to $380 million, net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of September 27, 2020, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $43.6 billion and $26.5 billion, respectively. As of December 29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $45.3 billion and $20.1 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of September 27, 2020, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $811 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2020 and 2019, net of tax: September 27, 2020 September 29, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 39 — — — — 39 — Amount of gain or (loss) recognized in AOCI — — — 39 — — — — 39 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 (81) (13) — (8) (8) (77) 1,911 — 1 Amount of gain or (loss) recognized in AOCI 16 156 (36) — (41) (23) (197) 1,939 — 5 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 84 — — — 89 — Amount of gain or (loss) recognized in AOCI $ — — — 65 — — — — 159 — The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2020 and 2019, net of tax: September 27, 2020 September 29, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 118 — — — — 117 — Amount of gain or (loss) recognized in AOCI — — — 118 — — — — 117 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 10 (316) (121) — (10) (43) (213) 1,808 — 9 Amount of gain or (loss) recognized in AOCI 25 330 (156) — (55) (29) (543) 1,847 — 15 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 265 — — — — 207 — Amount of gain or (loss) recognized in AOCI $ — — — 790 — — — — 299 — The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months ended in 2020 and 2019: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Foreign Exchange Contracts Other (income) expense $ 1 (13) 66 (101) The following table is the effect of net investment hedges for the fiscal third quarters ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Debt $ (169) 162 Interest (income) expense — — Cross Currency interest rate swaps $ (234) 152 Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal nine months ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Debt $ (217) 176 Interest (income) expense — — Cross Currency interest rate swaps $ 407 465 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 29, 2019 September 27, 2020 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 161 (169) 1,140 1,140 Equity Investments without readily determinable value $ 712 (36) 66 742 742 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $48 million of the decrease in the fair value reflected in net income were the result of impairments. There were $12 million of increase in fair value reflected in net income due to changes in observable prices. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of September 27, 2020 and December 29, 2019 were as follows: September 27, 2020 December 29, 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 612 — 612 209 Interest rate contracts (2)(3) — 635 — 635 693 Total — 1,247 — 1,247 902 Liabilities: Forward foreign exchange contracts — 327 — 327 426 Interest rate contracts (3) — 382 — 382 193 Total — 709 — 709 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 64 — 64 23 Liabilities: Forward foreign exchange contracts — 56 — 56 33 Other Investments: Equity investments (4) 1,140 — — 1,140 1,148 Debt securities (5) — 13,391 — 13,391 4,368 Other Liabilities Contingent consideration (6) $ — — 636 636 1,715 Gross to Net Derivative Reconciliation September 27, 2020 December 29, 2019 (Dollars in Millions) Total Gross Assets $ 1,311 925 Credit Support Agreement (CSA) (1,117) (841) Total Net Asset 194 84 Total Gross Liabilities 765 652 Credit Support Agreement (CSA) (737) (586) Total Net Liabilities $ 28 66 Summarized information about changes in liabilities for contingent consideration is as follows: September 27, 2020 September 29, 2019 (Dollars in Millions) Beginning Balance $ 1,715 $ 397 Changes in estimated fair value (7) (1,088) 117 Additions 107 1,133 Payments (98) (9) Ending Balance $ 636 $ 1,638 (1) December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current other assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $608 million and $1,631 million (primarily related to Auris Health at December 29, 2019), classified as non-current other liabilities as of September 27, 2020 and December 29, 2019, respectively. Includes $28 million and $84 million classified as current liabilities as of September 27, 2020 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense. For additional details see Note 10 t o the Consolidated Financial Statements. The Company's cash, cash equivalents and current marketable securities as of September 27, 2020 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,231 — — 2,231 2,231 Non-U.S. sovereign securities (1) 647 — — 647 — 647 U.S. reverse repurchase agreements 3,094 — — 3,094 3,094 — Other reverse repurchase agreements 430 — — 430 430 Corporate debt securities (1) 1,843 — — 1,843 571 1,272 Money market funds 8,485 — — 8,485 8,485 Time deposits (1) 660 — — 660 660 Subtotal 17,390 — — 17,390 15,471 1,919 Unrealized Gain Unrealized Loss U.S. Gov't securities 13,133 1 — 13,134 3,483 9,651 Other sovereign securities 10 — — 10 — 10 Corporate debt securities 247 — — 247 11 236 Subtotal available for sale debt (2) $ 13,390 1 — 13,391 3,494 9,897 Total cash, cash equivalents and current marketable securities $ 30,780 1 — 30,781 18,965 11,816 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. In the fiscal year ended December 29, 2019 the carrying amount was the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of September 27, 2020 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 13,368 13,369 Due after one year through five years 22 22 Due after five years through ten years — — Total debt securities $ 13,390 13,391 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 27, 2020: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,078 5,093 Non-Current Debt 2.45% Notes due 2021 350 358 0.250% Notes due 2022 (1B Euro 1.1641) 1,163 1,172 2.25% Notes due 2022 998 1,025 6.73% Debentures due 2023 250 299 3.375% Notes due 2023 803 881 2.05% Notes due 2023 499 518 0.650% Notes due 2024 (750MM Euro 1.1641) 870 899 5.50% Notes due 2024 (500 MM GBP 1.2757) 634 768 2.625% Notes due 2025 748 813 0.55% Notes due 2025 (1) 996 990 2.45% Notes due 2026 1,994 2,180 2.95% Notes due 2027 997 1,119 0.95% Notes due 2027 (1) 1,494 1,510 2.90% Notes due 2028 1,494 1,680 1.150% Notes due 2028 (750MM Euro 1.1641) 867 960 6.95% Notes due 2029 297 441 1.30% Notes due 2030 (1) 1,743 1,739 4.95% Debentures due 2033 498 690 4.375% Notes due 2033 855 1,128 1.650% Notes due 2035 (1.5B Euro 1.1641) 1,731 2,101 3.55% Notes due 2036 989 1,197 5.95% Notes due 2037 992 1,536 3.625% Notes due 2037 1,488 1,819 3.40% Notes due 2038 991 1,176 5.85% Debentures due 2038 696 1,094 4.50% Debentures due 2040 539 737 2.10% Notes due 2040 (1) 986 991 4.85% Notes due 2041 297 421 4.50% Notes due 2043 495 689 3.70% Notes due 2046 1,974 2,478 3.75% Notes due 2047 991 1,258 3.50% Notes due 2048 742 921 2.25% Notes due 2050 (1) 984 984 2.45% Notes due 2060 (1) 1,228 1,230 Other 7 10 Total Non-Current Debt $ 32,680 37,812 The weighted average effective interest rate on non-current debt is 2.85%. The excess of the estimated fair value over the carrying value of debt was $3.0 billion at December 29, 2019. The Current Debt balance as of September 27, 2020 includes $3.0 billion of commercial paper which has a weighted average interest rate of 0.15% and a weighted average maturity of 1.2 months. There was no commercial paper as of December 29, 2019. (1) In the fiscal third quarter of 2020, the Company issued senior unsecured notes for a total of $7.5 billion. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 27, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal nine months of 2020 and 2019 were 12.6% an d 15.3%, respectively. In the fiscal third quarter of 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF, including the step-up transitional provisions, can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. During the fiscal first quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes. During the second fiscal quarter of 2020, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., “step-up”) for its assets. As a result, the Company recorded additional deferred tax benefits in the second fiscal quarter of 2020 to recognize this step-up. Consequently, the benefit recorded related to Swiss Tax reform in the first nine months of fiscal 2020 was approximately $0.4 billion, or 2.7% benefit to the Company’s fiscal nine months effective tax rate, inclusive of the impact of U.S. GILTI deferred taxes. Comparatively, in the fiscal third quarter of 2019, the Company recorded a tax benefit from the enactment of Swiss tax reform which reduced the effective rate for the fiscal nine months of 2019 by 3.0%. The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. In the fiscal third quarter of 2019, the Company recorded additional unrecognized tax benefit liabilities which increased the effective tax rate for the fiscal nine months of 2019 by approximately 2.0%. In the fiscal third quarter of 2020, the Company recorded additional net unrecognized tax benefit liabilities which increased the effective tax rate for the fiscal nine months of 2020 by approximately 1.1%. Additionally, the following items impacted the Company's effective tax rate as compared to the same period in the prior fiscal year: • the impact of the agreement in principle to settle opioid litigation (see Note 21 to the Consolidated Financial Statements) in the fiscal third quarter of 2019, which was recorded in the U.S., at an effective tax rate of 23.0%. In the fiscal third quarter of 2020, the Company reduced the effective tax rate of this agreement in principle to 21.4%. • the reduced income in lower tax jurisdictions due to the ongoing COVID-19 pandemic • the 2019 divestiture gain related to Advanced Sterilization Products (ASP) which was primarily taxed in the U.S. • the accrual of additional legal costs, including an additional $1.0 billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4%, in fiscal nine months of 2020 (see Notes 9 and 11 to the Consolidated Financial Statements for more details). The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested; reduction of a contingent consideration liability related to the 2019 Auris Health acquisition; and reversal of some of its international unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the first fiscal three quarters of 2020. As of September 27, 2020, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010 through 2012. The Company currently expects completion of this audit in the fiscal year 2020. As of September 27, 2020, the Company has classified unrecognized tax benefits and related interest of approximately $0.1 billion as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet. This is the amount expected to be paid over the next 12 months with respect to the IRS audit. During the first fiscal quarter of 2020, the Company made a payment of approximately $0.6 billion to the U.S. Treasury with respect to the 2010-2012 tax audit in anticipation of a final settlement. The completion of this tax audit may result in additional adjustments to the Company’s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	9 Months Ended
	Sep. 27, 2020
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters and fiscal nine months of 2020 and 2019 include the following components: Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Service cost $ 330 275 72 68 979 828 216 205 Interest cost 238 273 33 46 715 822 99 138 Expected return on plan assets (617) (578) (2) (2) (1,839) (1,742) (5) (5) Amortization of prior service cost/(credit) — 1 (7) (7) 1 3 (23) (23) Recognized actuarial losses 224 145 36 32 669 435 107 97 Curtailments and settlements — (4) — — 19 3 — — Net periodic benefit cost $ 175 112 132 137 544 349 394 412 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal nine months ended September 27, 2020, the Company contributed $364 million and $27 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 27, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 29, 2019 $ (8,705) — (6,891) (295) (15,891) Net change (741) 1 587 1,106 953 September 27, 2020 $ (9,446) 1 (6,304) 811 (14,938) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 27, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters and fiscal nine months ended September 27, 2020 and September 29, 2019: Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Basic net earnings per share $ 1.35 0.67 4.93 4.19 Average shares outstanding — basic 2,632.5 2,635.2 2,633.0 2,649.5 Potential shares exercisable under stock option plans 115.7 117.8 120.2 137.6 Less: shares which could be repurchased under treasury stock method (78.9) (83.8) (82.4) (99.7) Convertible debt shares — 0.7 — 0.7 Average shares outstanding — diluted 2,669.3 2,669.9 2,670.8 2,688.1 Diluted net earnings per share $ 1.33 0.66 4.86 4.13 The diluted net earnings per share calculation for the fiscal third quarter ended September 27, 2020 excluded 20 million shares related to stock options, as the exercise price of these options was greater than their average market value. In the fiscal third quarter ended September 27, 2020 the Company did not have convertible debt. The diluted net earnings per share calculation for the fiscal third quarter ended September 29, 2019 excluded 19 million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal third quarter ended September 29, 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal nine months ended September 27, 2020 excluded 17 million shares related to stock options, as the exercise price of these options was greater than their average market value. In the fiscal nine months ended September 27, 2020 the Company did not have convertible debt. The diluted net earnings per share calculation for the fiscal nine months ended September 29, 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal nine months ended September 29, 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense.

Segments of Business and Geogra

Segments of Business and Geographic Areas	9 Months Ended
	Sep. 27, 2020
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 27, September 29, Percent September 27, September 29, Percent Change Consumer Health* OTC U.S. $ 601 477 26.0 % $ 1,917 1,468 30.6 % International 541 621 (12.9) 1,722 1,781 (3.3) Worldwide 1,142 1,098 4.0 3,639 3,249 12.0 Skin Health/Beauty U.S. 572 559 2.4 1,767 1,810 (2.4) International 577 592 (2.7) 1,506 1,633 (7.8) Worldwide 1,149 1,151 (0.2) 3,273 3,443 (5.0) Oral Care U.S. 164 156 5.5 510 462 10.4 International 248 223 10.7 694 673 3.0 Worldwide 412 379 8.5 1,204 1,135 6.0 Baby Care U.S. 91 91 (1.0) 279 277 0.5 International 302 326 (7.2) 831 977 (14.9) Worldwide 393 417 (5.9) 1,110 1,254 (11.5) Women's Health U.S. 3 3 (6.9) 10 9 7.3 International 227 252 (9.6) 654 724 (9.6) Worldwide 230 255 (9.6) 664 733 (9.4) Wound Care/Other U.S. 125 109 15.2 370 343 8.0 International 64 59 7.4 175 173 1.3 Worldwide 189 168 12.5 545 516 5.8 TOTAL Consumer Health U.S. 1,556 1,394 11.6 4,853 4,369 11.1 International 1,958 2,075 (5.6) 5,582 5,962 (6.4) Worldwide 3,514 3,469 1.3 10,435 10,331 1.0 * Previously referred to as Consumer PHARMACEUTICAL Immunology U.S. 2,558 2,582 (0.9) 7,330 7,124 2.9 International 1,230 1,129 9.0 3,619 3,304 9.5 Worldwide 3,789 3,711 2.1 10,950 10,428 5.0 REMICADE ® U.S. 634 749 (15.4) 1,852 2,324 (20.3) U.S. Exports 78 88 (11.3) 321 226 42.1 International 209 299 (30.1) 673 795 (15.3) Worldwide 921 1,136 (18.9) 2,846 3,345 (14.9) SIMPONI / SIMPONI ARIA ® U.S. 312 313 (0.4) 840 857 (2.0) International 280 273 2.4 827 816 1.3 Worldwide 592 586 0.9 1,667 1,673 (0.4) STELARA ® U.S. 1,313 1,212 8.4 3,668 3,152 16.4 International 634 487 30.3 1,795 1,509 19.0 Worldwide 1,947 1,698 14.7 5,463 4,661 17.2 TREMFYA ® U.S. 222 221 0.4 650 565 15.0% International 105 69 54.4 316 177 78.7 Worldwide 327 290 13.1 965 742 30.2% OTHER IMMUNOLOGY U.S. — — — — — — International 3 2 35.6 9 8 12.4 Worldwide 3 2 35.6 9 8 12.4 Infectious Diseases U.S. 413 418 (1.1) 1,265 1,162 8.9 International 451 421 7.0 1,397 1,385 0.9 Worldwide 864 839 3.0 2,662 2,547 4.5 EDURANT ® / rilpivirine U.S. 11 12 (12.0) 33 36 (8.6) International 226 206 9.3 684 603 13.3 Worldwide 236 218 8.1 716 639 12.1 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 379 373 1.5 1,154 1,032 11.8 International 147 135 9.1 461 534 (13.7) Worldwide 526 508 3.5 1,615 1,566 3.1 OTHER INFECTIOUS DISEASES U.S. 24 33 (26.6) 79 94 (16.6) International 78 80 (2.3) 252 248 1.8 Worldwide 102 113 (9.4) 331 342 (3.2) Neuroscience U.S. 759 785 (3.5) 2,285 2,172 5.2 International 846 810 4.5 2,565 2,590 (1.0) Worldwide 1,605 1,595 0.6 4,850 4,762 1.8 CONCERTA ® / methylphenidate U.S. 43 84 (49.2) 150 196 (23.6) International 107 109 (2.0) 319 348 (8.2) Worldwide 149 193 (22.6) 469 544 (13.8) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 585 554 5.6 1,704 1,543 10.5 International 341 297 14.9 983 916 7.3 Worldwide 926 851 8.8 2,688 2,459 9.3 RISPERDAL CONSTA ® U.S. 70 79 (11.0) 220 237 (6.9) International 81 89 (7.8) 254 292 (12.7) Worldwide 152 167 (9.3) 475 528 (10.1) OTHER NEUROSCIENCE U.S. 60 68 (11.3) 210 196 7.1 International 317 316 0.3 1,008 1,035 (2.6) Worldwide 377 384 (1.8) 1,218 1,231 (1.1) Oncology U.S. 1,267 1,171 8.2 3,623 3,146 15.2 International 1,862 1,590 17.1 5,310 4,830 9.9 Worldwide 3,129 2,761 13.3 8,933 7,976 12.0 DARZALEX ® U.S. 585 402 46.0 1,540 1,123 37.2 International 514 363 41.5 1,397 1,045 33.7 Worldwide 1,099 765 43.8 2,937 2,168 35.5 ERLEADA ® U.S. 152 74 * 407 194 * International 55 12 * 112 22 * Worldwide 206 86 * 519 216 * IMBRUVICA ® U.S. 450 447 0.7 1,329 1,163 14.2 International 581 475 22.5 1,682 1,373 22.5 Worldwide 1,031 921 11.9 3,011 2,536 18.7 VELCADE ® U.S. — — — — — — International 105 149 (30.1) 311 636 (51.2) Worldwide 105 149 (30.1) 311 636 (51.2) ZYTIGA ® / abiraterone acetate U.S. 58 233 (75.2) 284 616 (53.9) International 532 508 4.8 1,564 1,502 4.1 Worldwide 590 741 (20.4) 1,848 2,118 (12.7) OTHER ONCOLOGY U.S. 21 17 35.3 63 51 25.8 International 76 83 (8.8) 244 252 (3.1) Worldwide 98 100 (1.7) 308 303 1.7 Pulmonary Hypertension U.S. 510 427 19.4 1,541 1,296 18.9 International 239 227 5.2 742 704 5.3 Worldwide 749 654 14.5 2,283 2,000 14.1 OPSUMIT ® U.S. 244 206 18.1 729 581 25.3 International 148 140 5.5 458 419 9.3 Worldwide 392 347 13.0 1,187 1,001 18.6 UPTRAVI ® U.S. 226 185 22.4 692 536 29.1 International 34 25 32.3 100 75 33.1 Worldwide 260 210 23.6 792 611 29.6 OTHER PULMONARY HYPERTENSION U.S. 40 36 11.5 121 179 (32.3) International 57 61 (6.7) 183 210 (12.7) Worldwide 97 96 0.1 304 388 (21.7) Cardiovascular / Metabolism / Other U.S. 931 955 (2.6) 2,574 2,804 (8.2) International 351 360 (2.7) 1,052 1,131 (7.1) Worldwide 1,281 1,316 (2.6) 3,625 3,936 (7.9) XARELTO ® U.S. 630 613 2.9 1,716 1,704 0.7 International — — — — — — Worldwide 630 613 2.9 1,716 1,704 0.7 INVOKANA ® / INVOKAMET ® U.S. 156 125 24.7 405 411 (1.6) International 68 55 24.7 173 147 18.0 Worldwide 224 179 24.7 578 558 3.6 PROCRIT ® / EPREX ® U.S. 69 126 (45.4) 215 387 (44.5) International 63 72 (12.2) 208 220 (5.5) Worldwide 132 198 (33.3) 423 607 (30.4) OTHER U.S. 75 91 (17.9) 238 302 (21.4) International 219 234 (6.2) 670 765 (12.3) Worldwide 294 325 (9.5) 908 1,067 (14.9) TOTAL PHARMACEUTICAL U.S. 6,438 6,340 1.5 18,619 17,705 5.2 International 4,980 4,537 9.7 14,685 13,945 5.3 Worldwide 11,418 10,877 5.0 33,304 31,650 5.2 MEDICAL DEVICES Interventional Solutions U.S. 399 357 11.8 1,019 1,066 (4.4) International 437 382 14.0 1,134 1,156 (2.0) Worldwide 836 741 12.9 2,153 2,223 (3.1) Orthopaedics U.S. 1,308 1,301 0.6 3,427 3,950 (13.2) International 774 837 (7.5) 2,145 2,616 (18.0) Worldwide 2,083 2,138 (2.6) 5,572 6,566 (15.1) HIPS U.S. 221 204 8.7 564 633 (10.9) International 124 133 (7.2) 344 428 (19.8) Worldwide 345 336 2.4 908 1,061 (14.5) KNEES U.S. 205 209 (1.9) 527 650 (19.0) International 102 136 (24.8) 298 435 (31.5) Worldwide 308 344 (10.9) 825 1,085 (24.0) TRAUMA U.S. 433 415 4.2 1,194 1,239 (3.6) International 253 262 (3.4) 698 795 (12.2) Worldwide 685 677 1.3 1,892 2,034 (7.0) SPINE, SPORTS & OTHER U.S. 449 472 (4.9) 1,142 1,427 (20.0) International 295 306 (3.4) 805 957 (15.8) Worldwide 745 778 (4.3) 1,947 2,384 (18.3) Surgery U.S. 913 940 (3.0) 2,247 2,867 (21.7) International 1,239 1,371 (9.6) 3,556 4,192 (15.2) Worldwide 2,152 2,311 (6.9) 5,803 7,059 (17.8) ADVANCED U.S. 421 409 3.0 1,079 1,209 (10.7) International 579 602 (3.9) 1,644 1,811 (9.2) Worldwide 1,000 1,010 (1.1) 2,723 3,019 (9.8) GENERAL U.S. 492 531 (7.6) 1,168 1,658 (29.6) International 660 769 (14.1) 1,912 2,381 (19.7) Worldwide 1,152 1,301 (11.4) 3,080 4,040 (23.8) Vision U.S. 473 459 3.1 1,160 1,366 (15.1) International 608 734 (17.2) 1,683 2,117 (20.5) Worldwide 1,081 1,193 (9.4) 2,843 3,483 (18.4) CONTACT LENSES / OTHER U.S. 375 339 10.9 924 993 (6.9) International 455 555 (18.1) 1,274 1,566 (18.7) Worldwide 830 893 (7.1) 2,198 2,559 (14.1) SURGICAL U.S. 98 120 (18.9) 236 373 (36.8) International 153 180 (14.6) 409 551 (25.7) Worldwide 251 299 (16.3) 645 923 (30.2) TOTAL MEDICAL DEVICES U.S. 3,092 3,057 1.2 7,852 9,249 (15.1) International 3,058 3,326 (8.1) 8,518 10,082 (15.5) Worldwide 6,150 6,383 (3.6) 16,370 19,331 (15.3) WORLDWIDE U.S. 11,086 10,791 2.7 31,324 31,323 0.0 International 9,996 9,938 0.6 28,785 29,989 (4.0) Worldwide $ 21,082 20,729 1.7 % $ 60,109 61,312 (2.0) % *Percentage greater than 100% or not meaningful EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 27, September 29, Percent September 27, September 29, Percent Change Consumer Health (1) $ 191 653 (70.8) % $ 993 1,800 (44.8) % Pharmaceutical (2) 3,439 (222) * 11,787 5,786 * Medical Devices (3) 1,010 1,392 (27.4) 2,681 6,078 (55.9) Segment earnings before provision for taxes 4,640 1,823 * 15,461 13,664 13.2 Less: Expense not allocated to segments (4) 239 176 611 554 Worldwide income before tax $ 4,401 1,647 * $ 14,850 13,110 13.3 % *Percentage greater than 100% or not meaningful (1) Consumer Health • Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal nine months of 2019. • Includes litigation expense of $0.5 billion in the fiscal third quarter of 2020, primarily talc related costs, including certain settlements. Includes litigation expense of $1.2 billion and $0.2 billion in both the fiscal nine months of 2020 and 2019, primarily talc related costs, including certain settlements. • Includes amortization expense of $0.1 billion in both the fiscal third quarters of 2020 and 2019, respectively and $0.3 billion in both the fiscal nine months of 2020 and 2019, respectively. • Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2020 and 2019, respectively. (2) Pharmaceutical • Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal nine months of 2019. • Includes litigation expense of $1.0 billion and $4.0 billion in the fiscal third quarters of 2020 and 2019 and $1.0 billion and $4.3 billion in the fiscal nine months of 2020 and 2019, respectively. Litigation expense in all periods is primarily related to the agreement in principle to settle opioid litigation. • Includes an unrealized loss on securities of $0.1 billion in the fiscal third quarter of 2019. Includes an unrealized gain on securities of $0.2 billion in both the fiscal nine months of 2020 and 2019, respectively. • Includes a research and development expense of $0.3 billion in the fiscal nine months of 2019, for an upfront payment related to argenx. • Includes amortization expense of $0.8 billion in both the fiscal third quarters of 2020 and 2019. Includes amortization expense of $2.4 billion in both the fiscal nine months of 2020 and 2019. • Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2020 and 2019, respectively. • Includes Actelion acquisition related costs of $0.1 billion in the fiscal nine months of 2019. • In the fiscal second and third quarters of 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.8 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) Medical Devices • Includes a contingent consideration reversal of $0.2 billion in the fiscal third quarter of 2020 and $1.1 billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal nine months of 2019. • Includes litigation expense of $0.3 billion in the fiscal nine months of 2019. • Includes a restructuring related charge of $0.1 billion and amortization expense of $0.2 billion in both the fiscal third quarters of 2020 and 2019. • Includes a restructuring related charge of $0.2 billion and amortization expense of $0.7 billion in both the fiscal nine months of 2020 and 2019. • Includes an in-process research and development expense of $0.1 billion in the fiscal third quarter of 2020 and fiscal nine months of 2020. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 27, 2020 September 29, 2019 Percent September 27, 2020 September 29, 2019 Percent Change United States $ 11,086 10,791 2.7 % $ 31,324 31,323 0.0 % Europe 4,819 4,461 8.0 13,709 13,803 (0.7) Western Hemisphere, excluding U.S. 1,296 1,488 (12.9) 3,931 4,446 (11.6) Asia-Pacific, Africa 3,881 3,989 (2.7) 11,145 11,740 (5.1) Total $ 21,082 20,729 1.7 % $ 60,109 61,312 (2.0) %

Business Combinations and Dives

Business Combinations and Divestitures	9 Months Ended
	Sep. 27, 2020
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES Subsequent to the fiscal third quarter, on October 1, 2020, the Company completed the acquisition of Momenta Pharmaceuticals, Inc. (Momenta) a company that discovers and develops novel therapies for immune-mediated diseases, for a purchase price of approximately $6.5 billion, primarily allocated to IPR&D. In the fiscal fourth quarter of 2020, the transaction will be accounted for as a business combination and included in the Pharmaceutical segment. During the fiscal third quarter of 2020, the Company sold 11.8 million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company. The transaction resulted in gross proceeds of approximately CHF337 million ($357 million) based on a sales price of CHF 28.55/share and an immaterial net loss. The Company currently has rights to at least an additional 38.7 million shares (or approximately 20% of Idorsia equity) through a convertible loan with a principal amount of CHF 445 million (due June 2027). Idorsia also has access to an approximate CHF 243 million credit facility with the Company. As of September 27, 2020, Idorsia has not made any draw-downs under the credit facility. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion. On April 1, 2019, the Company completed the divestiture of its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $2.0 billion. On April 1, 2019, the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D, for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. During the fiscal nine months of 2020, the Company recorded Other income of approximately $1.1 billion for the reversal of all of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company’s current timelines. During the fiscal third quarter of 2020, the Company recorded a partial IPR&D impairment charge of $0.1 billion related to timing and progression of the digital surgery platforms. On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. The Company treated this transaction as a business combination and included it in the Consumer Health segment. During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities assumed of $0.4 billion. The adjustments made since the date of acquisition were $0.1 billion to intangible assets, accrued liabilities, deferred taxes on income and property, plant and equipment with the offset to goodwill. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 27, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation evolves. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of September 27, 2020, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of September 27, 2020, in the United States there were approximately 600 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 8,200 with respect to the PINNACLE ® Acetabular Cup System; 15,400 with respect to pelvic meshes; 10,400 with respect to RISPERDAL ® ; 15,000 with respect to XARELTO ® ; 21,800 with respect to body powders containing talc; 300 with respect to INVOKANA ® ; and 4,000 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the Québec Superior Court and the Supreme Court of British Columbia. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. The Company is appealing the decision. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss. The class actions in Canada are expected to be discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh product s. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Claims have also been filed against Ethicon and Johnson & Johnson alleging personal injuries arising from the PROCEED ® Mesh and PROCEED ® Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch products. In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE™ Polypropylene Hernia System (“PHS”) cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a recent verdict in October 2019 of $8 billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8 million by the trial judge. The Company and plaintiff are each appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson (J&J); and JPI’s collaboration partner for XARELTO ® , Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&J announced an agreement in principle to the settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation in the United States District Court for the District of New Jersey. In the multi-district litigation, the parties have sought to exclude experts, through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied plaintiffs’ attempt to limit the scope of testimony of certain of the Company’s witnesses. With this ruling made, case-specific discovery has begun, per the court’s directive to proceed. In talc cases that have previously gone to trial, the Company has obtained defense verdicts in a number of these cases but there have also been verdicts against the Company, many of which have been reversed on appeal. Most recently, in June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion, reducing the overall award to $2.1 billion. The Company has filed an application for transfer of the case to the Missouri Supreme Court. The Company continues to believe that it has strong grounds for the appeal of this verdict, as well as other verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for settlement of certain cases and claims in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. Based on such claims as well as indemnity and insurance claims the Company has against Imerys, the Company petitioned the United States District Court for the District of Delaware to establish federal jurisdiction of the state court talc lawsuits under the Bankruptcy Code. The Company's petition was denied and the state court talc lawsuits that have been removed to federal court on such basis have been remanded. The Company previously proposed to resolve Imerys' (and the Company’s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company’s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants’ committee filed their Plan of Reorganization and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements. The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus’s claims against the Company. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. Discovery is underway. In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation . In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. Four of the shareholders who had sent demands are plaintiffs in th e In re Johnson & Johnson Talc Stockholder Derivative Litigation . In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. A lawsuit is pending in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act relating to JOHNSON’S ® Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson & Johnson and Johnson & Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. The case has been stayed by the court pending an initial status conference. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company is cooperating with government inquiries and continues to produce documents as required in response. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ’132, ’730 and ’280 patents, based on the district court’s claim construction and reserving its right to appeal that construction, leaving only the ’426 patent at issue before the district court. In May 2019, DePuy filed a motion for summary judgment of non-infringement of the claims of the ’426 patent. In November 2019, judgment was entered in favor of DePuy. In December 2019, MedIdea filed a notice of appeal and the appeal is fully briefed. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (’735); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (’284), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310 (’310); 9,084,608; 9,241,759 (’759) and 9,113,882, and seeking damages and an injunction. In June 2020, after a bench trial, the district court entered judgment in Ethicon’s favor. In July 2020, Covidien filed a notice of appeal, and Ethicon filed a cross appeal. In August 2020, the parties agreed to dismiss their respective appeals. In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412 (’412). Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. Trial is scheduled to begin in March 2021. In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® PDS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 (’296) and 7,033,603 (’603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020, the USPTO denied institution of the ’296 patent IPR and granted institution of the ’603 patent IPR. UT dismissed the ’603 patent from the suit and no longer accuses PDS ® Plus Antibacterial Sutures or STRATAFIX ® PDS ® Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed. In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200); 6,491,701 (’701); 6,522,906 (’906); 6,800,056 (’056); 8,142,447 (’447); 8,620,473 (’473); 8,801,601 (’601); and 9,452,276 (’276) based on Auris’ Monarch™ Platform. Auris filed IPR Petitions with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. Intuitive subsequently dropped the ’200, ’473 and ’701 patents from the suit. In December 2019, the USPTO instituted review of the ’601 patent and denied review of the ’056 patent. In February and March 2020, the USPTO instituted review of the ’200, ’447, ’701 and ’906 patents and denied review of the ’276 patent. The district court trial is scheduled to begin in June 2021. In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713, 537 by one or more of the following products: ZERO-P-VA™ Spacer, ZERO-P ® Spacer, ZERO-P NATURAL™ Plate, SYNFIX ® LR Spacer and SYNFIX ® Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States Distri

Restructuring

Restructuring	9 Months Ended
	Sep. 27, 2020
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the Global Supply Chain restructuring strategic collaborations see Note 10 to the Consolidated Financial Statements. In the fiscal third quarter of 2020, the Company recorded a pre-tax charge of $130 million, which is included on the following lines of the Consolidated Statement of Earnings, $68 million in restructuring, $32 million in cost of products sold and $30 million in other (income) expense. In the fiscal nine months of 2020, the Company recorded a pre-tax charge of $363 million, which is included on the following lines of the Consolidated Statement of Earnings, $187 million in restructuring, $69 million in cost of products sold and $107 million in other (income) expense. Total project costs of approximately $1.2 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal nine months of 2020: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 Current year activity: Charges — 55 308 363 Cash payments (18) — (297) (315) Settled non cash — (55) (17) (3) (72) Reserve balance, September 27, 2020 (1) $ 146 — 10 156 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended	9 Months Ended
	Jun. 28, 2020	Sep. 27, 2020
Accounting Policies [Abstract]
Use of Estimates		Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of September 27, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended September 27, 2020, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
New Accounting Standards Recently Adopted		New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There were no new material accounting standards issued in the fiscal third quarter of 2020 that impacted the Company. Recently Adopted Accounting Standards There were no new accounting standards adopted in the fiscal third quarter of 2020.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	9 Months Ended
	Sep. 27, 2020
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 27, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) September 27, 2020 December 29, 2019 Raw materials and supplies $ 1,363 1,117 Goods in process 1,916 1,832 Finished goods 6,320 6,071 Total inventories (1) $ 9,599 9,020 (1) See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 27, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) September 27, 2020 December 29, 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 38,381 36,634 Less accumulated amortization 16,098 13,154 Patents and trademarks — net 22,283 23,480 Customer relationships and other intangibles — gross 22,455 22,056 Less accumulated amortization 10,427 9,462 Customer relationships and other intangibles — net* 12,028 12,594 Intangible assets with indefinite lives: Trademarks 6,995 6,922 Purchased in-process research and development (1) 5,700 4,647 Total intangible assets with indefinite lives 12,695 11,569 Total intangible assets — net $ 47,006 47,643 *The majority is comprised of customer relationships
Goodwill	Goodwill as of September 27, 2020 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1 183 184 Currency translation/Other 171 280 33 484 Goodwill at September 27, 2020 $ 9,907 9,450 14,950 34,307
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 3,900

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 27, 2020
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2020 and 2019, net of tax: September 27, 2020 September 29, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 39 — — — — 39 — Amount of gain or (loss) recognized in AOCI — — — 39 — — — — 39 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 3 (81) (13) — (8) (8) (77) 1,911 — 1 Amount of gain or (loss) recognized in AOCI 16 156 (36) — (41) (23) (197) 1,939 — 5 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 84 — — — 89 — Amount of gain or (loss) recognized in AOCI $ — — — 65 — — — — 159 — The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2020 and 2019, net of tax: September 27, 2020 September 29, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 118 — — — — 117 — Amount of gain or (loss) recognized in AOCI — — — 118 — — — — 117 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 10 (316) (121) — (10) (43) (213) 1,808 — 9 Amount of gain or (loss) recognized in AOCI 25 330 (156) — (55) (29) (543) 1,847 — 15 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 265 — — — — 207 — Amount of gain or (loss) recognized in AOCI $ — — — 790 — — — — 299 — The following table is the effect of net investment hedges for the fiscal third quarters ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Debt $ (169) 162 Interest (income) expense — — Cross Currency interest rate swaps $ (234) 152 Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal nine months ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Debt $ (217) 176 Interest (income) expense — — Cross Currency interest rate swaps $ 407 465 Interest (income) expense — —
Schedule of Derivatives Recorded in Consolidated Balance Sheet
Schedule of Effect of Derivatives not Designated as Hedging Instruments	Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Foreign Exchange Contracts Other (income) expense $ 1 (13) 66 (101)
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 29, 2019 September 27, 2020 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 161 (169) 1,140 1,140 Equity Investments without readily determinable value $ 712 (36) 66 742 742 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of September 27, 2020 and December 29, 2019 were as follows: September 27, 2020 December 29, 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 612 — 612 209 Interest rate contracts (2)(3) — 635 — 635 693 Total — 1,247 — 1,247 902 Liabilities: Forward foreign exchange contracts — 327 — 327 426 Interest rate contracts (3) — 382 — 382 193 Total — 709 — 709 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 64 — 64 23 Liabilities: Forward foreign exchange contracts — 56 — 56 33 Other Investments: Equity investments (4) 1,140 — — 1,140 1,148 Debt securities (5) — 13,391 — 13,391 4,368 Other Liabilities Contingent consideration (6) $ — — 636 636 1,715 Gross to Net Derivative Reconciliation September 27, 2020 December 29, 2019 (Dollars in Millions) Total Gross Assets $ 1,311 925 Credit Support Agreement (CSA) (1,117) (841) Total Net Asset 194 84 Total Gross Liabilities 765 652 Credit Support Agreement (CSA) (737) (586) Total Net Liabilities $ 28 66 Summarized information about changes in liabilities for contingent consideration is as follows: September 27, 2020 September 29, 2019 (Dollars in Millions) Beginning Balance $ 1,715 $ 397 Changes in estimated fair value (7) (1,088) 117 Additions 107 1,133 Payments (98) (9) Ending Balance $ 636 $ 1,638 (1) December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current other assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $608 million and $1,631 million (primarily related to Auris Health at December 29, 2019), classified as non-current other liabilities as of September 27, 2020 and December 29, 2019, respectively. Includes $28 million and $84 million classified as current liabilities as of September 27, 2020 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense. For additional details see Note 10 t o the Consolidated Financial Statements.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of September 27, 2020 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,231 — — 2,231 2,231 Non-U.S. sovereign securities (1) 647 — — 647 — 647 U.S. reverse repurchase agreements 3,094 — — 3,094 3,094 — Other reverse repurchase agreements 430 — — 430 430 Corporate debt securities (1) 1,843 — — 1,843 571 1,272 Money market funds 8,485 — — 8,485 8,485 Time deposits (1) 660 — — 660 660 Subtotal 17,390 — — 17,390 15,471 1,919 Unrealized Gain Unrealized Loss U.S. Gov't securities 13,133 1 — 13,134 3,483 9,651 Other sovereign securities 10 — — 10 — 10 Corporate debt securities 247 — — 247 11 236 Subtotal available for sale debt (2) $ 13,390 1 — 13,391 3,494 9,897 Total cash, cash equivalents and current marketable securities $ 30,780 1 — 30,781 18,965 11,816 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of September 27, 2020 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 13,368 13,369 Due after one year through five years 22 22 Due after five years through ten years — — Total debt securities $ 13,390 13,391
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 27, 2020: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,078 5,093 Non-Current Debt 2.45% Notes due 2021 350 358 0.250% Notes due 2022 (1B Euro 1.1641) 1,163 1,172 2.25% Notes due 2022 998 1,025 6.73% Debentures due 2023 250 299 3.375% Notes due 2023 803 881 2.05% Notes due 2023 499 518 0.650% Notes due 2024 (750MM Euro 1.1641) 870 899 5.50% Notes due 2024 (500 MM GBP 1.2757) 634 768 2.625% Notes due 2025 748 813 0.55% Notes due 2025 (1) 996 990 2.45% Notes due 2026 1,994 2,180 2.95% Notes due 2027 997 1,119 0.95% Notes due 2027 (1) 1,494 1,510 2.90% Notes due 2028 1,494 1,680 1.150% Notes due 2028 (750MM Euro 1.1641) 867 960 6.95% Notes due 2029 297 441 1.30% Notes due 2030 (1) 1,743 1,739 4.95% Debentures due 2033 498 690 4.375% Notes due 2033 855 1,128 1.650% Notes due 2035 (1.5B Euro 1.1641) 1,731 2,101 3.55% Notes due 2036 989 1,197 5.95% Notes due 2037 992 1,536 3.625% Notes due 2037 1,488 1,819 3.40% Notes due 2038 991 1,176 5.85% Debentures due 2038 696 1,094 4.50% Debentures due 2040 539 737 2.10% Notes due 2040 (1) 986 991 4.85% Notes due 2041 297 421 4.50% Notes due 2043 495 689 3.70% Notes due 2046 1,974 2,478 3.75% Notes due 2047 991 1,258 3.50% Notes due 2048 742 921 2.25% Notes due 2050 (1) 984 984 2.45% Notes due 2060 (1) 1,228 1,230 Other 7 10 Total Non-Current Debt $ 32,680 37,812

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	9 Months Ended
	Sep. 27, 2020
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters and fiscal nine months of 2020 and 2019 include the following components: Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Service cost $ 330 275 72 68 979 828 216 205 Interest cost 238 273 33 46 715 822 99 138 Expected return on plan assets (617) (578) (2) (2) (1,839) (1,742) (5) (5) Amortization of prior service cost/(credit) — 1 (7) (7) 1 3 (23) (23) Recognized actuarial losses 224 145 36 32 669 435 107 97 Curtailments and settlements — (4) — — 19 3 — — Net periodic benefit cost $ 175 112 132 137 544 349 394 412

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 27, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 29, 2019 $ (8,705) — (6,891) (295) (15,891) Net change (741) 1 587 1,106 953 September 27, 2020 $ (9,446) 1 (6,304) 811 (14,938)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 27, 2020
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters and fiscal nine months ended September 27, 2020 and September 29, 2019: Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019 Basic net earnings per share $ 1.35 0.67 4.93 4.19 Average shares outstanding — basic 2,632.5 2,635.2 2,633.0 2,649.5 Potential shares exercisable under stock option plans 115.7 117.8 120.2 137.6 Less: shares which could be repurchased under treasury stock method (78.9) (83.8) (82.4) (99.7) Convertible debt shares — 0.7 — 0.7 Average shares outstanding — diluted 2,669.3 2,669.9 2,670.8 2,688.1 Diluted net earnings per share $ 1.33 0.66 4.86 4.13

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	9 Months Ended
	Sep. 27, 2020
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 27, September 29, Percent September 27, September 29, Percent Change Consumer Health* OTC U.S. $ 601 477 26.0 % $ 1,917 1,468 30.6 % International 541 621 (12.9) 1,722 1,781 (3.3) Worldwide 1,142 1,098 4.0 3,639 3,249 12.0 Skin Health/Beauty U.S. 572 559 2.4 1,767 1,810 (2.4) International 577 592 (2.7) 1,506 1,633 (7.8) Worldwide 1,149 1,151 (0.2) 3,273 3,443 (5.0) Oral Care U.S. 164 156 5.5 510 462 10.4 International 248 223 10.7 694 673 3.0 Worldwide 412 379 8.5 1,204 1,135 6.0 Baby Care U.S. 91 91 (1.0) 279 277 0.5 International 302 326 (7.2) 831 977 (14.9) Worldwide 393 417 (5.9) 1,110 1,254 (11.5) Women's Health U.S. 3 3 (6.9) 10 9 7.3 International 227 252 (9.6) 654 724 (9.6) Worldwide 230 255 (9.6) 664 733 (9.4) Wound Care/Other U.S. 125 109 15.2 370 343 8.0 International 64 59 7.4 175 173 1.3 Worldwide 189 168 12.5 545 516 5.8 TOTAL Consumer Health U.S. 1,556 1,394 11.6 4,853 4,369 11.1 International 1,958 2,075 (5.6) 5,582 5,962 (6.4) Worldwide 3,514 3,469 1.3 10,435 10,331 1.0 * Previously referred to as Consumer PHARMACEUTICAL Immunology U.S. 2,558 2,582 (0.9) 7,330 7,124 2.9 International 1,230 1,129 9.0 3,619 3,304 9.5 Worldwide 3,789 3,711 2.1 10,950 10,428 5.0 REMICADE ® U.S. 634 749 (15.4) 1,852 2,324 (20.3) U.S. Exports 78 88 (11.3) 321 226 42.1 International 209 299 (30.1) 673 795 (15.3) Worldwide 921 1,136 (18.9) 2,846 3,345 (14.9) SIMPONI / SIMPONI ARIA ® U.S. 312 313 (0.4) 840 857 (2.0) International 280 273 2.4 827 816 1.3 Worldwide 592 586 0.9 1,667 1,673 (0.4) STELARA ® U.S. 1,313 1,212 8.4 3,668 3,152 16.4 International 634 487 30.3 1,795 1,509 19.0 Worldwide 1,947 1,698 14.7 5,463 4,661 17.2 TREMFYA ® U.S. 222 221 0.4 650 565 15.0% International 105 69 54.4 316 177 78.7 Worldwide 327 290 13.1 965 742 30.2% OTHER IMMUNOLOGY U.S. — — — — — — International 3 2 35.6 9 8 12.4 Worldwide 3 2 35.6 9 8 12.4 Infectious Diseases U.S. 413 418 (1.1) 1,265 1,162 8.9 International 451 421 7.0 1,397 1,385 0.9 Worldwide 864 839 3.0 2,662 2,547 4.5 EDURANT ® / rilpivirine U.S. 11 12 (12.0) 33 36 (8.6) International 226 206 9.3 684 603 13.3 Worldwide 236 218 8.1 716 639 12.1 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 379 373 1.5 1,154 1,032 11.8 International 147 135 9.1 461 534 (13.7) Worldwide 526 508 3.5 1,615 1,566 3.1 OTHER INFECTIOUS DISEASES U.S. 24 33 (26.6) 79 94 (16.6) International 78 80 (2.3) 252 248 1.8 Worldwide 102 113 (9.4) 331 342 (3.2) Neuroscience U.S. 759 785 (3.5) 2,285 2,172 5.2 International 846 810 4.5 2,565 2,590 (1.0) Worldwide 1,605 1,595 0.6 4,850 4,762 1.8 CONCERTA ® / methylphenidate U.S. 43 84 (49.2) 150 196 (23.6) International 107 109 (2.0) 319 348 (8.2) Worldwide 149 193 (22.6) 469 544 (13.8) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 585 554 5.6 1,704 1,543 10.5 International 341 297 14.9 983 916 7.3 Worldwide 926 851 8.8 2,688 2,459 9.3 RISPERDAL CONSTA ® U.S. 70 79 (11.0) 220 237 (6.9) International 81 89 (7.8) 254 292 (12.7) Worldwide 152 167 (9.3) 475 528 (10.1) OTHER NEUROSCIENCE U.S. 60 68 (11.3) 210 196 7.1 International 317 316 0.3 1,008 1,035 (2.6) Worldwide 377 384 (1.8) 1,218 1,231 (1.1) Oncology U.S. 1,267 1,171 8.2 3,623 3,146 15.2 International 1,862 1,590 17.1 5,310 4,830 9.9 Worldwide 3,129 2,761 13.3 8,933 7,976 12.0 DARZALEX ® U.S. 585 402 46.0 1,540 1,123 37.2 International 514 363 41.5 1,397 1,045 33.7 Worldwide 1,099 765 43.8 2,937 2,168 35.5 ERLEADA ® U.S. 152 74 * 407 194 * International 55 12 * 112 22 * Worldwide 206 86 * 519 216 * IMBRUVICA ® U.S. 450 447 0.7 1,329 1,163 14.2 International 581 475 22.5 1,682 1,373 22.5 Worldwide 1,031 921 11.9 3,011 2,536 18.7 VELCADE ® U.S. — — — — — — International 105 149 (30.1) 311 636 (51.2) Worldwide 105 149 (30.1) 311 636 (51.2) ZYTIGA ® / abiraterone acetate U.S. 58 233 (75.2) 284 616 (53.9) International 532 508 4.8 1,564 1,502 4.1 Worldwide 590 741 (20.4) 1,848 2,118 (12.7) OTHER ONCOLOGY U.S. 21 17 35.3 63 51 25.8 International 76 83 (8.8) 244 252 (3.1) Worldwide 98 100 (1.7) 308 303 1.7 Pulmonary Hypertension U.S. 510 427 19.4 1,541 1,296 18.9 International 239 227 5.2 742 704 5.3 Worldwide 749 654 14.5 2,283 2,000 14.1 OPSUMIT ® U.S. 244 206 18.1 729 581 25.3 International 148 140 5.5 458 419 9.3 Worldwide 392 347 13.0 1,187 1,001 18.6 UPTRAVI ® U.S. 226 185 22.4 692 536 29.1 International 34 25 32.3 100 75 33.1 Worldwide 260 210 23.6 792 611 29.6 OTHER PULMONARY HYPERTENSION U.S. 40 36 11.5 121 179 (32.3) International 57 61 (6.7) 183 210 (12.7) Worldwide 97 96 0.1 304 388 (21.7) Cardiovascular / Metabolism / Other U.S. 931 955 (2.6) 2,574 2,804 (8.2) International 351 360 (2.7) 1,052 1,131 (7.1) Worldwide 1,281 1,316 (2.6) 3,625 3,936 (7.9) XARELTO ® U.S. 630 613 2.9 1,716 1,704 0.7 International — — — — — — Worldwide 630 613 2.9 1,716 1,704 0.7 INVOKANA ® / INVOKAMET ® U.S. 156 125 24.7 405 411 (1.6) International 68 55 24.7 173 147 18.0 Worldwide 224 179 24.7 578 558 3.6 PROCRIT ® / EPREX ® U.S. 69 126 (45.4) 215 387 (44.5) International 63 72 (12.2) 208 220 (5.5) Worldwide 132 198 (33.3) 423 607 (30.4) OTHER U.S. 75 91 (17.9) 238 302 (21.4) International 219 234 (6.2) 670 765 (12.3) Worldwide 294 325 (9.5) 908 1,067 (14.9) TOTAL PHARMACEUTICAL U.S. 6,438 6,340 1.5 18,619 17,705 5.2 International 4,980 4,537 9.7 14,685 13,945 5.3 Worldwide 11,418 10,877 5.0 33,304 31,650 5.2 MEDICAL DEVICES Interventional Solutions U.S. 399 357 11.8 1,019 1,066 (4.4) International 437 382 14.0 1,134 1,156 (2.0) Worldwide 836 741 12.9 2,153 2,223 (3.1) Orthopaedics U.S. 1,308 1,301 0.6 3,427 3,950 (13.2) International 774 837 (7.5) 2,145 2,616 (18.0) Worldwide 2,083 2,138 (2.6) 5,572 6,566 (15.1) HIPS U.S. 221 204 8.7 564 633 (10.9) International 124 133 (7.2) 344 428 (19.8) Worldwide 345 336 2.4 908 1,061 (14.5) KNEES U.S. 205 209 (1.9) 527 650 (19.0) International 102 136 (24.8) 298 435 (31.5) Worldwide 308 344 (10.9) 825 1,085 (24.0) TRAUMA U.S. 433 415 4.2 1,194 1,239 (3.6) International 253 262 (3.4) 698 795 (12.2) Worldwide 685 677 1.3 1,892 2,034 (7.0) SPINE, SPORTS & OTHER U.S. 449 472 (4.9) 1,142 1,427 (20.0) International 295 306 (3.4) 805 957 (15.8) Worldwide 745 778 (4.3) 1,947 2,384 (18.3) Surgery U.S. 913 940 (3.0) 2,247 2,867 (21.7) International 1,239 1,371 (9.6) 3,556 4,192 (15.2) Worldwide 2,152 2,311 (6.9) 5,803 7,059 (17.8) ADVANCED U.S. 421 409 3.0 1,079 1,209 (10.7) International 579 602 (3.9) 1,644 1,811 (9.2) Worldwide 1,000 1,010 (1.1) 2,723 3,019 (9.8) GENERAL U.S. 492 531 (7.6) 1,168 1,658 (29.6) International 660 769 (14.1) 1,912 2,381 (19.7) Worldwide 1,152 1,301 (11.4) 3,080 4,040 (23.8) Vision U.S. 473 459 3.1 1,160 1,366 (15.1) International 608 734 (17.2) 1,683 2,117 (20.5) Worldwide 1,081 1,193 (9.4) 2,843 3,483 (18.4) CONTACT LENSES / OTHER U.S. 375 339 10.9 924 993 (6.9) International 455 555 (18.1) 1,274 1,566 (18.7) Worldwide 830 893 (7.1) 2,198 2,559 (14.1) SURGICAL U.S. 98 120 (18.9) 236 373 (36.8) International 153 180 (14.6) 409 551 (25.7) Worldwide 251 299 (16.3) 645 923 (30.2) TOTAL MEDICAL DEVICES U.S. 3,092 3,057 1.2 7,852 9,249 (15.1) International 3,058 3,326 (8.1) 8,518 10,082 (15.5) Worldwide 6,150 6,383 (3.6) 16,370 19,331 (15.3) WORLDWIDE U.S. 11,086 10,791 2.7 31,324 31,323 0.0 International 9,996 9,938 0.6 28,785 29,989 (4.0) Worldwide $ 21,082 20,729 1.7 % $ 60,109 61,312 (2.0) % *Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 27, September 29, Percent September 27, September 29, Percent Change Consumer Health (1) $ 191 653 (70.8) % $ 993 1,800 (44.8) % Pharmaceutical (2) 3,439 (222) * 11,787 5,786 * Medical Devices (3) 1,010 1,392 (27.4) 2,681 6,078 (55.9) Segment earnings before provision for taxes 4,640 1,823 * 15,461 13,664 13.2 Less: Expense not allocated to segments (4) 239 176 611 554 Worldwide income before tax $ 4,401 1,647 * $ 14,850 13,110 13.3 % *Percentage greater than 100% or not meaningful (1) Consumer Health • Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal nine months of 2019. • Includes litigation expense of $0.5 billion in the fiscal third quarter of 2020, primarily talc related costs, including certain settlements. Includes litigation expense of $1.2 billion and $0.2 billion in both the fiscal nine months of 2020 and 2019, primarily talc related costs, including certain settlements. • Includes amortization expense of $0.1 billion in both the fiscal third quarters of 2020 and 2019, respectively and $0.3 billion in both the fiscal nine months of 2020 and 2019, respectively. • Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2020 and 2019, respectively. (2) Pharmaceutical • Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal nine months of 2019. • Includes litigation expense of $1.0 billion and $4.0 billion in the fiscal third quarters of 2020 and 2019 and $1.0 billion and $4.3 billion in the fiscal nine months of 2020 and 2019, respectively. Litigation expense in all periods is primarily related to the agreement in principle to settle opioid litigation. • Includes an unrealized loss on securities of $0.1 billion in the fiscal third quarter of 2019. Includes an unrealized gain on securities of $0.2 billion in both the fiscal nine months of 2020 and 2019, respectively. • Includes a research and development expense of $0.3 billion in the fiscal nine months of 2019, for an upfront payment related to argenx. • Includes amortization expense of $0.8 billion in both the fiscal third quarters of 2020 and 2019. Includes amortization expense of $2.4 billion in both the fiscal nine months of 2020 and 2019. • Includes a restructuring related charge of $0.1 billion in both the fiscal nine months of 2020 and 2019, respectively. • Includes Actelion acquisition related costs of $0.1 billion in the fiscal nine months of 2019. • In the fiscal second and third quarters of 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.8 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) Medical Devices • Includes a contingent consideration reversal of $0.2 billion in the fiscal third quarter of 2020 and $1.1 billion in the fiscal nine months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal nine months of 2019. • Includes litigation expense of $0.3 billion in the fiscal nine months of 2019. • Includes a restructuring related charge of $0.1 billion and amortization expense of $0.2 billion in both the fiscal third quarters of 2020 and 2019. • Includes a restructuring related charge of $0.2 billion and amortization expense of $0.7 billion in both the fiscal nine months of 2020 and 2019. • Includes an in-process research and development expense of $0.1 billion in the fiscal third quarter of 2020 and fiscal nine months of 2020.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 27, 2020 September 29, 2019 Percent September 27, 2020 September 29, 2019 Percent Change United States $ 11,086 10,791 2.7 % $ 31,324 31,323 0.0 % Europe 4,819 4,461 8.0 13,709 13,803 (0.7) Western Hemisphere, excluding U.S. 1,296 1,488 (12.9) 3,931 4,446 (11.6) Asia-Pacific, Africa 3,881 3,989 (2.7) 11,145 11,740 (5.1) Total $ 21,082 20,729 1.7 % $ 60,109 61,312 (2.0) %

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 27, 2020
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal nine months of 2020: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 Current year activity: Charges — 55 308 363 Cash payments (18) — (297) (315) Settled non cash — (55) (17) (3) (72) Reserve balance, September 27, 2020 (1) $ 146 — 10 156 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,363	$ 1,117
Goods in process	1,916	1,832
Finished goods	6,320	6,071
Total inventories	$ 9,599	$ 9,020

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 12,695	$ 11,569
Total intangible assets - net	47,006	47,643
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	6,995	6,922
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	5,700	4,647
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	38,381	36,634
Less accumulated amortization	16,098	13,154
Finite-Lived Intangible Assets, Net	22,283	23,480
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	22,455	22,056
Less accumulated amortization	10,427	9,462
Finite-Lived Intangible Assets, Net	$ 12,028	$ 12,594

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	9 Months Ended
	Sep. 27, 2020USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 33,639
Goodwill, related to acquisitions	184
Currency translation/Other	484
Goodwill End of Period	34,307
Consumer Health*
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,736
Goodwill, related to acquisitions	0
Currency translation/Other	171
Goodwill End of Period	9,907
PHARMACEUTICAL
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,169
Goodwill, related to acquisitions	1
Currency translation/Other	280
Goodwill End of Period	9,450
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	14,734
Goodwill, related to acquisitions	183
Currency translation/Other	33
Goodwill End of Period	$ 14,950

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019	Mar. 29, 2020	Dec. 29, 2019
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 12,695		$ 12,695			$ 11,569
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	1,200	$ 1,100	$ 3,400	$ 3,300
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life			12 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life			21 years
Purchased In-Process Research And Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 5,700		$ 5,700			$ 4,647
Purchased In-Process Research And Development | bermekimab
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)					$ 800
Purchased In-Process Research And Development | Verb Surgical Inc.
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)					$ 400

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Sep. 27, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 4,500
2021	4,300
2022	4,100
2023	4,100
2024	$ 3,900

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019	Dec. 29, 2019
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	$ 1,140		$ 1,140		$ 1,148
Accumulated other comprehensive income on derivatives, after tax	811		$ 811
Reclassification of foreign exchange contracts into earnings, period			next 12 months
Maximum length of time for hedge exposure			18 months
Unrealized gains on equity investments	$ 1	$ 0	$ 1	$ 1
Weighted average interest rate on non-current debt	2.85%		2.85%
Excess of the estimated fair value over the carrying value of debt					3,000
Current Debt	$ 5,078		$ 5,078		1,202
Reversal of contingent consideration			1,088	(117)
Commercial Paper
Derivative [Line Items]
Current Debt	$ 3,000		$ 3,000
Weighted average interest rate	0.15%		0.15%
Term			1 month 6 days
Forward foreign exchange contracts
Derivative [Line Items]
Collateral Already Posted, Aggregate Fair Value	$ 380		$ 380
Derivative, Notional Amount	43,600		43,600		45,300
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Notional Amount	26,500		26,500		20,100
Interest Rate Contract
Derivative [Line Items]
Derivative Asset, Noncurrent					1
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss			(48)
Equity, Fair Value Adjustment, Change In Observable Price			12
Equity Securities without Readily Determinable Fair Value, Amount	742		742		$ 712
Changes in Fair Value Reflected in Net Income			(36)
Equity Investments with readily determinable value | Equity Securities
Derivative [Line Items]
Changes in Fair Value Reflected in Net Income			161
Other (income) expense
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Fair Value Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	39	39	118	117
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	39	39	118	117
Fair Value Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	3	(8)	10	(43)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	16	(23)	25	(29)
Cash Flow Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Cost of Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(81)	(77)	(316)	(213)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	156	(197)	330	(543)
Cash Flow Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0		0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(13)	1,911	(121)	1,808
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(36)	1,939	(156)	1,847
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	84	89	265	207
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	65	159	790	299
Cash Flow Hedging [Member] | Other (income) expense | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(8)	1	(10)	9
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(41)	5	(55)	15
Cash Flow Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 636		$ 636		$ 1,715
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income	24	$ 1,955	(54)	$ 1,885
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	199	1,922	1,052	1,706
Other (income) expense
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Forward foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Collateral Already Posted, Aggregate Fair Value	380		380
Derivative, Notional Amount	43,600		43,600		45,300
Cross currency interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	26,500		26,500		$ 20,100
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	39	39	118	117
Unrealized gain (loss) arising during period	39	39	118	117
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	16	(23)	25	(29)
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	3	(8)	10	(43)
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	156	(197)	330	(543)
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(81)	(77)	(316)	(213)
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(36)	1,939	(156)	1,847
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(13)	1,911	(121)	1,808
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(41)	5	(55)	15
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(8)	1	(10)	9
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0		0	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	65	159	790	299
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	$ 84	$ 89	$ 265	$ 207

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Business Combination, Contingent Consideration, Liability	$ 636	$ 1,715
Carrying Amount of the Hedged Liability	$ 28	$ 66

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 636		$ 636		$ 1,715
Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 1	$ (13)	$ 66	$ (101)

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 636		$ 636		$ 1,715
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	(169)	$ 162	(217)	$ 176
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	$ (234)	$ 152	$ 407	$ 465

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 27, 2020	Dec. 29, 2019
Other Investment Not Readily Marketable [Line Items]
Business Combination, Contingent Consideration, Liability	$ 636	$ 1,715
Equity Investment [Roll Forward]
Non Current Other Assets	6,131	$ 5,695
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	1,148
Changes in Fair Value Reflected in Net Income	161
Sales/ Purchases/Other	(169)
Carrying value, end of period	1,140
Non Current Other Assets	1,140
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	712
Changes in Fair Value Reflected in Net Income	(36)
Sales/ Purchases/Other	66
Carrying value, end of period	742
Non Current Other Assets	$ 742

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Dec. 29, 2019	Apr. 01, 2019
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 1,247
Derivatives designated as hedging instruments : Liabilities	709
Available-for-sale Securities, Equity Securities	1,140		$ 1,148
Available-for-sale Securities	13,391		4,368
Total Gross Assets	1,311		925
Credit Support Agreement (CSA)	(1,117)		(841)
Total Net Asset	194		84
Total Gross Liabilities	765		652
Credit Support Agreement (CSA)	(737)		(586)
Total Net Liabilities	28		66
Beginning Balance	636	$ 1,638
Changes in estimated fair value (7)	(1,088)	117
Additions	107	1,133
Payments	(98)	(9)
Ending Balance	1,715	397
Contingent consideration	636		1,715
Contingent consideration reversal	(1,148)	$ 0
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	1,140		1,148
Available-for-sale Securities	0
Contingent consideration	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,247		902
Derivatives designated as hedging instruments : Liabilities	709		619
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	13,391
Contingent consideration	0
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Contingent consideration	636		1,715
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	635
Derivatives designated as hedging instruments : Liabilities	382
Derivative Assets, Noncurrent			1
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	635		693
Derivatives designated as hedging instruments : Liabilities	382		193
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivative, Notional Amount	43,600		45,300
Derivatives designated as hedging instruments : Assets	612
Derivatives designated as hedging instruments : Liabilities	327
Derivatives not designated as hedging instruments : Assets	64
Derivatives not designated as hedging instruments : Liabilities	56
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	612		209
Derivatives designated as hedging instruments : Liabilities	327		426
Derivatives not designated as hedging instruments : Assets	64		23
Derivatives not designated as hedging instruments : Liabilities	56		33
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Cross currency interest rate swaps
Financial assets and liabilities at fair value
Derivative, Notional Amount	26,500		20,100
Auris Health
Financial assets and liabilities at fair value
Contingent consideration				$ 2,350
Contingent consideration reversal	(1,148)
Other Noncurrent Liabilities | Auris Health
Financial assets and liabilities at fair value
Contingent consideration	608		1,631
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration	$ 28		$ 84

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 13,391	$ 4,368
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	18,965	17,305
Marketable securities	11,816	$ 1,982
Total cash, cash equivalents and current marketable securities, Carrying Amount	30,780
Total cash, cash equivalents and current marketable securities, Unrecognized Gain	1
Total cash, cash equivalents and current marketable securities, Unrecognized Loss	0
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	30,781
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	17,390
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	17,390
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	15,471
Marketable securities	1,919
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,231
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,231
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,231
Held-to-maturity Securities | Non-U.S. sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	647
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	647
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	647
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	3,094
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	3,094
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,094
Marketable securities	0
Held-to-maturity Securities | Other reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	430
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	430
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	430
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,843
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,843
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	571
Marketable securities	1,272
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	8,485
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	8,485
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	8,485
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	660
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	660
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	660
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	13,390
Available-for-sale Securities, Unrecognized Gain	1
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	13,391
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,494
Marketable securities	9,897
Available-for-sale Securities | Non-U.S. sovereign securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	10
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	10
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	10
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	247
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	247
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	11
Marketable securities	236
Available-for-sale Securities | US Treasury and Government [Member]
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	13,133
Available-for-sale Securities, Unrecognized Gain	1
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	13,134
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,483
Marketable securities	$ 9,651

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Sep. 27, 2020USD ($)
Cost Basis
Due within one year	$ 13,368
Due after one year through five years	22
Due after five years through ten years	0
Total debt securities	13,390
Fair Value
Due within one year	13,369
Due after one year through five years	22
Due after five years through ten years	0
Total debt securities	$ 13,391

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Sep. 27, 2020	Dec. 29, 2019
Financial Liabilities
Current Debt	$ 5,078	$ 1,202
Non-Current Debt
Non-Current Debt	32,680	$ 26,494
Senior notes
Non-Current Debt
Non-Current Debt	7,500
Carrying Amount
Financial Liabilities
Current Debt	5,078
Non-Current Debt
Non-Current Debt	32,680
Estimated Fair Value
Financial Liabilities
Current Debt	5,093
Non-Current Debt
Non-Current Debt	$ 37,812
2.45% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 350
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 358
0.250% Notes due 2022 (1B Euro 1.1641)
Non-Current Debt
Stated interest rate (as a percent)	0.25%
0.250% Notes due 2022 (1B Euro 1.1641) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,163
0.250% Notes due 2022 (1B Euro 1.1641) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,172
2.25% Notes due 2022
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.25% Notes due 2022 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 998
2.25% Notes due 2022 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,025
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 299
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 803
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 881
2.05% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 499
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 518
0.650% Notes due 2024 (750MM Euro 1.1641)
Non-Current Debt
Stated interest rate (as a percent)	0.65%
0.650% Notes due 2024 (750MM Euro 1.1641) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 870
0.650% Notes due 2024 (750MM Euro 1.1641) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 899
5.50% Notes due 2024 (500 MM GBP 1.2757)
Non-Current Debt
Stated interest rate (as a percent)	5.50%
5.50% Notes due 2024 (500 MM GBP 1.2757) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 634
5.50% Notes due 2024 (500 MM GBP 1.2757) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 768
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 748
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 813
0.550 Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	0.55%
0.55% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 996
0.55% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 990
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,994
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,180
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,119
0.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	0.95%
0.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,494
0.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,510
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,494
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,680
1.150% Notes due 2028 (750MM Euro 1.1641)
Non-Current Debt
Stated interest rate (as a percent)	1.15%
1.150% Notes due 2028 (750MM Euro 1.1641) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 867
1.150% Notes due 2028 (750MM Euro 1.1641) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 960
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 441
1.300% Notes due 2030
Non-Current Debt
Stated interest rate (as a percent)	1.30%
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 690
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 855
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,128
1.650% Notes due 2035 (1.5B Euro 1.1641)
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.650% Notes due 2035 (1.5B Euro 1.1641) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,731
1.650% Notes due 2035 (1.5B Euro 1.1641) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,101
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 989
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,197
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,536
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,488
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,819
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,176
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 696
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,094
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 539
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 737
2.10% Notes due 2040
Non-Current Debt
Stated interest rate (as a percent)	2.10%
2.10% Notes due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 986
2.10% Notes due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 991
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 421
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 689
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,974
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,478
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,258
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 742
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 921
2.250% Notes due 2050
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.450% Notes due 2060
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.450% Notes due 2060 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,228
2.450% Notes due 2060 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	1,230
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	7
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	10
1.30% Notes due 2030 | Carrying Amount
Non-Current Debt
Non-Current Debt	1,743
1.30% Notes due 2030 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	1,739
2.25% Notes due 2050 | Carrying Amount
Non-Current Debt
Non-Current Debt	984
2.25% Notes due 2050 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 984

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	3 Months Ended			9 Months Ended
	Sep. 27, 2020	Mar. 29, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Income Tax (Textuals)
Worldwide effective income tax rate (as a percent)				12.60%	15.30%
Deferred tax benefit related to TRAF		$ 0.3		$ 0.4
Deferred tax liability related to TRAF		0.2
Deferred tax benefit related to TRAF, percent				2.70%	3.00%
Impact to effective tax rate, percent					2.00%
Net impact to tax rate due to change in contingent consideration liability	1.10%
Effective income tax rate from revised agreement (as a percent)	21.40%		23.00%	21.40%
Accrued legal fees, revised agreement from litigation settlement	$ 1			$ 1
Unrecognized tax benefits	3.3			3.3
Accrued Taxes On Income [Member]
Income Tax (Textuals)
Unrecognized tax benefits	$ 0.1			$ 0.1
Internal Revenue Service (IRS) [Member]
Income Tax (Textuals)
Payment on unrecognized tax benefit liability		$ 0.6

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 330	$ 275	$ 979	$ 828
Interest cost	238	273	715	822
Expected return on plan assets	(617)	(578)	(1,839)	(1,742)
Amortization of prior service cost/(credit)	0	1	1	3
Recognized actuarial losses	224	145	669	435
Curtailments and settlements	0	(4)	19	3
Net periodic benefit cost	175	112	544	349
Other Benefit Plans
Components of net periodic benefit cost
Service cost	72	68	216	205
Interest cost	33	46	99	138
Expected return on plan assets	(2)	(2)	(5)	(5)
Amortization of prior service cost/(credit)	(7)	(7)	(23)	(23)
Recognized actuarial losses	36	32	107	97
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 132	$ 137	$ 394	$ 412

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	9 Months Ended
	Sep. 27, 2020USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 364
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 27

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 62,978	$ 60,785	$ 59,471	$ 59,752
Net change	595	(564)	953	(311)
Ending Balance	64,473	58,210	64,473	58,210
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(8,705)
Net change			(741)
Ending Balance	(9,446)		(9,446)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			0
Net change			1
Ending Balance	1		1
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(6,891)
Net change			587
Ending Balance	(6,304)		(6,304)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(295)
Net change			1,106
Ending Balance	811		811
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(15,533)	(14,969)	(15,891)	(15,222)
Net change	595	(564)	953	(311)
Ending Balance	$ (14,938)	$ (15,533)	$ (14,938)	$ (15,533)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.35	$ 0.67	$ 4.93	$ 4.19
Average shares outstanding — basic	2,632,500	2,635,200	2,633,000	2,649,500
Potential shares exercisable under stock option plans	115,700	117,800	120,200	137,600
Less: shares which could be repurchased under treasury stock method	(78,900)	(83,800)	(82,400)	(99,700)
Convertible debt shares	0	700	0	700
Average shares outstanding — diluted	2,669,300	2,669,900	2,670,800	2,688,100
Diluted net earnings per share	$ 1.33	$ 0.66	$ 4.86	$ 4.13
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000	19,000	17,000

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Sales by segment of business
Sales to customers	$ 21,082	$ 20,729	$ 60,109	$ 61,312
Percent Change (as a percent)	1.70%		(2.00%)
U.S.
Sales by segment of business
Sales to customers	$ 11,086	10,791	$ 31,324	31,323
Percent Change (as a percent)	2.70%		0.00%
International
Sales by segment of business
Sales to customers	$ 9,996	9,938	$ 28,785	29,989
Percent Change (as a percent)	0.60%		(4.00%)
Consumer Health*
Sales by segment of business
Sales to customers	$ 3,514	3,469	$ 10,435	10,331
Percent Change (as a percent)	1.30%		1.00%
Consumer Health* | U.S.
Sales by segment of business
Sales to customers	$ 1,556	1,394	$ 4,853	4,369
Percent Change (as a percent)	11.60%		11.10%
Consumer Health* | International
Sales by segment of business
Sales to customers	$ 1,958	2,075	$ 5,582	5,962
Percent Change (as a percent)	(5.60%)		(6.40%)
Consumer Health* | OTC
Sales by segment of business
Sales to customers	$ 1,142	1,098	$ 3,639	3,249
Percent Change (as a percent)	4.00%		12.00%
Consumer Health* | OTC | U.S.
Sales by segment of business
Sales to customers	$ 601	477	$ 1,917	1,468
Percent Change (as a percent)	26.00%		30.60%
Consumer Health* | OTC | International
Sales by segment of business
Sales to customers	$ 541	621	$ 1,722	1,781
Percent Change (as a percent)	(12.90%)		(3.30%)
Consumer Health* | Skin Health/Beauty
Sales by segment of business
Sales to customers	$ 1,149	1,151	$ 3,273	3,443
Percent Change (as a percent)	(0.20%)		(5.00%)
Consumer Health* | Skin Health/Beauty | U.S.
Sales by segment of business
Sales to customers	$ 572	559	$ 1,767	1,810
Percent Change (as a percent)	2.40%		(2.40%)
Consumer Health* | Skin Health/Beauty | International
Sales by segment of business
Sales to customers	$ 577	592	$ 1,506	1,633
Percent Change (as a percent)	(2.70%)		(7.80%)
Consumer Health* | Oral Care
Sales by segment of business
Sales to customers	$ 412	379	$ 1,204	1,135
Percent Change (as a percent)	8.50%		6.00%
Consumer Health* | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 164	156	$ 510	462
Percent Change (as a percent)	5.50%		10.40%
Consumer Health* | Oral Care | International
Sales by segment of business
Sales to customers	$ 248	223	$ 694	673
Percent Change (as a percent)	10.70%		3.00%
Consumer Health* | Baby Care
Sales by segment of business
Sales to customers	$ 393	417	$ 1,110	1,254
Percent Change (as a percent)	(5.90%)		(11.50%)
Consumer Health* | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 91	91	$ 279	277
Percent Change (as a percent)	(1.00%)		0.50%
Consumer Health* | Baby Care | International
Sales by segment of business
Sales to customers	$ 302	326	$ 831	977
Percent Change (as a percent)	(7.20%)		(14.90%)
Consumer Health* | Women's Health
Sales by segment of business
Sales to customers	$ 230	255	$ 664	733
Percent Change (as a percent)	(9.60%)		(9.40%)
Consumer Health* | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 3	3	$ 10	9
Percent Change (as a percent)	(6.90%)		7.30%
Consumer Health* | Women's Health | International
Sales by segment of business
Sales to customers	$ 227	252	$ 654	724
Percent Change (as a percent)	(9.60%)		(9.60%)
Consumer Health* | Wound Care/Other
Sales by segment of business
Sales to customers	$ 189	168	$ 545	516
Percent Change (as a percent)	12.50%		5.80%
Consumer Health* | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 125	109	$ 370	343
Percent Change (as a percent)	15.20%		8.00%
Consumer Health* | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 64	59	$ 175	173
Percent Change (as a percent)	7.40%		1.30%
PHARMACEUTICAL
Sales by segment of business
Sales to customers	$ 11,418	10,877	$ 33,304	31,650
Percent Change (as a percent)	5.00%		5.20%
PHARMACEUTICAL | U.S.
Sales by segment of business
Sales to customers	$ 6,438	6,340	$ 18,619	17,705
Percent Change (as a percent)	1.50%		5.20%
PHARMACEUTICAL | International
Sales by segment of business
Sales to customers	$ 4,980	4,537	$ 14,685	13,945
Percent Change (as a percent)	9.70%		5.30%
PHARMACEUTICAL | Immunology
Sales by segment of business
Sales to customers	$ 3,789	3,711	$ 10,950	10,428
Percent Change (as a percent)	2.10%		5.00%
PHARMACEUTICAL | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,558	2,582	$ 7,330	7,124
Percent Change (as a percent)	(0.90%)		2.90%
PHARMACEUTICAL | Immunology | International
Sales by segment of business
Sales to customers	$ 1,230	1,129	$ 3,619	3,304
Percent Change (as a percent)	9.00%		9.50%
PHARMACEUTICAL | Immunology | REMICADE®
Sales by segment of business
Sales to customers	$ 921	1,136	$ 2,846	3,345
Percent Change (as a percent)	(18.90%)		(14.90%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S.
Sales by segment of business
Sales to customers	$ 634	749	$ 1,852	2,324
Percent Change (as a percent)	(15.40%)		(20.30%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports
Sales by segment of business
Sales to customers	$ 78	88	$ 321	226
Percent Change (as a percent)	(11.30%)		42.10%
PHARMACEUTICAL | Immunology | REMICADE® | International
Sales by segment of business
Sales to customers	$ 209	299	$ 673	795
Percent Change (as a percent)	(30.10%)		(15.30%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA®
Sales by segment of business
Sales to customers	$ 592	586	$ 1,667	1,673
Percent Change (as a percent)	0.90%		(0.40%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S.
Sales by segment of business
Sales to customers	$ 312	313	$ 840	857
Percent Change (as a percent)	(0.40%)		(2.00%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International
Sales by segment of business
Sales to customers	$ 280	273	$ 827	816
Percent Change (as a percent)	2.40%		1.30%
PHARMACEUTICAL | Immunology | STELARA®
Sales by segment of business
Sales to customers	$ 1,947	1,698	$ 5,463	4,661
Percent Change (as a percent)	14.70%		17.20%
PHARMACEUTICAL | Immunology | STELARA® | U.S.
Sales by segment of business
Sales to customers	$ 1,313	1,212	$ 3,668	3,152
Percent Change (as a percent)	8.40%		16.40%
PHARMACEUTICAL | Immunology | STELARA® | International
Sales by segment of business
Sales to customers	$ 634	487	$ 1,795	1,509
Percent Change (as a percent)	30.30%		19.00%
PHARMACEUTICAL | Immunology | TREMFYA®
Sales by segment of business
Sales to customers	$ 327	290	$ 965	742
Percent Change (as a percent)	13.10%		30.20%
PHARMACEUTICAL | Immunology | TREMFYA® | U.S.
Sales by segment of business
Sales to customers	$ 222	221	$ 650	565
Percent Change (as a percent)	0.40%		15.00%
PHARMACEUTICAL | Immunology | TREMFYA® | International
Sales by segment of business
Sales to customers	$ 105	69	$ 316	177
Percent Change (as a percent)	54.40%		78.70%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 3	2	$ 9	8
Percent Change (as a percent)	35.60%		12.40%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	$ 3	2	$ 9	8
Percent Change (as a percent)	35.60%		12.40%
PHARMACEUTICAL | Infectious Diseases
Sales by segment of business
Sales to customers	$ 864	839	$ 2,662	2,547
Percent Change (as a percent)	3.00%		4.50%
PHARMACEUTICAL | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 413	418	$ 1,265	1,162
Percent Change (as a percent)	(1.10%)		8.90%
PHARMACEUTICAL | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 451	421	$ 1,397	1,385
Percent Change (as a percent)	7.00%		0.90%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine
Sales by segment of business
Sales to customers	$ 236	218	$ 716	639
Percent Change (as a percent)	8.10%		12.10%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 11	12	$ 33	36
Percent Change (as a percent)	(12.00%)		(8.60%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International
Sales by segment of business
Sales to customers	$ 226	206	$ 684	603
Percent Change (as a percent)	9.30%		13.30%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
Sales by segment of business
Sales to customers	$ 526	508	$ 1,615	1,566
Percent Change (as a percent)	3.50%		3.10%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S.
Sales by segment of business
Sales to customers	$ 379	373	$ 1,154	1,032
Percent Change (as a percent)	1.50%		11.80%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International
Sales by segment of business
Sales to customers	$ 147	135	$ 461	534
Percent Change (as a percent)	9.10%		(13.70%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES
Sales by segment of business
Sales to customers	$ 102	113	$ 331	342
Percent Change (as a percent)	(9.40%)		(3.20%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.
Sales by segment of business
Sales to customers	$ 24	33	$ 79	94
Percent Change (as a percent)	(26.60%)		(16.60%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International
Sales by segment of business
Sales to customers	$ 78	80	$ 252	248
Percent Change (as a percent)	(2.30%)		1.80%
PHARMACEUTICAL | Neuroscience
Sales by segment of business
Sales to customers	$ 1,605	1,595	$ 4,850	4,762
Percent Change (as a percent)	0.60%		1.80%
PHARMACEUTICAL | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 759	785	$ 2,285	2,172
Percent Change (as a percent)	(3.50%)		5.20%
PHARMACEUTICAL | Neuroscience | International
Sales by segment of business
Sales to customers	$ 846	810	$ 2,565	2,590
Percent Change (as a percent)	4.50%		(1.00%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate
Sales by segment of business
Sales to customers	$ 149	193	$ 469	544
Percent Change (as a percent)	(22.60%)		(13.80%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 43	84	$ 150	196
Percent Change (as a percent)	(49.20%)		(23.60%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International
Sales by segment of business
Sales to customers	$ 107	109	$ 319	348
Percent Change (as a percent)	(2.00%)		(8.20%)
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
Sales by segment of business
Sales to customers	$ 926	851	$ 2,688	2,459
Percent Change (as a percent)	8.80%		9.30%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S.
Sales by segment of business
Sales to customers	$ 585	554	$ 1,704	1,543
Percent Change (as a percent)	5.60%		10.50%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International
Sales by segment of business
Sales to customers	$ 341	297	$ 983	916
Percent Change (as a percent)	14.90%		7.30%
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA®
Sales by segment of business
Sales to customers	$ 152	167	$ 475	528
Percent Change (as a percent)	(9.30%)		(10.10%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S.
Sales by segment of business
Sales to customers	$ 70	79	$ 220	237
Percent Change (as a percent)	(11.00%)		(6.90%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International
Sales by segment of business
Sales to customers	$ 81	89	$ 254	292
Percent Change (as a percent)	(7.80%)		(12.70%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 377	384	$ 1,218	1,231
Percent Change (as a percent)	(1.80%)		(1.10%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 60	68	$ 210	196
Percent Change (as a percent)	(11.30%)		7.10%
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 317	316	$ 1,008	1,035
Percent Change (as a percent)	0.30%		(2.60%)
PHARMACEUTICAL | Oncology
Sales by segment of business
Sales to customers	$ 3,129	2,761	$ 8,933	7,976
Percent Change (as a percent)	13.30%		12.00%
PHARMACEUTICAL | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,267	1,171	$ 3,623	3,146
Percent Change (as a percent)	8.20%		15.20%
PHARMACEUTICAL | Oncology | International
Sales by segment of business
Sales to customers	$ 1,862	1,590	$ 5,310	4,830
Percent Change (as a percent)	17.10%		9.90%
PHARMACEUTICAL | Oncology | DARZALEX®
Sales by segment of business
Sales to customers	$ 1,099	765	$ 2,937	2,168
Percent Change (as a percent)	43.80%		35.50%
PHARMACEUTICAL | Oncology | DARZALEX® | U.S.
Sales by segment of business
Sales to customers	$ 585	402	$ 1,540	1,123
Percent Change (as a percent)	46.00%		37.20%
PHARMACEUTICAL | Oncology | DARZALEX® | International
Sales by segment of business
Sales to customers	$ 514	363	$ 1,397	1,045
Percent Change (as a percent)	41.50%		33.70%
PHARMACEUTICAL | Oncology | ERLEADA
Sales by segment of business
Sales to customers	$ 206	86	$ 519	216
PHARMACEUTICAL | Oncology | ERLEADA | U.S.
Sales by segment of business
Sales to customers	152	74	407	194
PHARMACEUTICAL | Oncology | ERLEADA | International
Sales by segment of business
Sales to customers	55	12	112	22
PHARMACEUTICAL | Oncology | IMBRUVICA®
Sales by segment of business
Sales to customers	$ 1,031	921	$ 3,011	2,536
Percent Change (as a percent)	11.90%		18.70%
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S.
Sales by segment of business
Sales to customers	$ 450	447	$ 1,329	1,163
Percent Change (as a percent)	0.70%		14.20%
PHARMACEUTICAL | Oncology | IMBRUVICA® | International
Sales by segment of business
Sales to customers	$ 581	475	$ 1,682	1,373
Percent Change (as a percent)	22.50%		22.50%
PHARMACEUTICAL | Oncology | VELCADE®
Sales by segment of business
Sales to customers	$ 105	149	$ 311	636
Percent Change (as a percent)	(30.10%)		(51.20%)
PHARMACEUTICAL | Oncology | VELCADE® | U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Oncology | VELCADE® | International
Sales by segment of business
Sales to customers	$ 105	149	$ 311	636
Percent Change (as a percent)	(30.10%)		(51.20%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate
Sales by segment of business
Sales to customers	$ 590	741	$ 1,848	2,118
Percent Change (as a percent)	(20.40%)		(12.70%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 58	233	$ 284	616
Percent Change (as a percent)	(75.20%)		(53.90%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 532	508	$ 1,564	1,502
Percent Change (as a percent)	4.80%		4.10%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 98	100	$ 308	303
Percent Change (as a percent)	(1.70%)		1.70%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 21	17	$ 63	51
Percent Change (as a percent)	35.30%		25.80%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales to customers	$ 76	83	$ 244	252
Percent Change (as a percent)	(8.80%)		(3.10%)
PHARMACEUTICAL | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 749	654	$ 2,283	2,000
Percent Change (as a percent)	14.50%		14.10%
PHARMACEUTICAL | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 510	427	$ 1,541	1,296
Percent Change (as a percent)	19.40%		18.90%
PHARMACEUTICAL | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 239	227	$ 742	704
Percent Change (as a percent)	5.20%		5.30%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT®
Sales by segment of business
Sales to customers	$ 392	347	$ 1,187	1,001
Percent Change (as a percent)	13.00%		18.60%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S.
Sales by segment of business
Sales to customers	$ 244	206	$ 729	581
Percent Change (as a percent)	18.10%		25.30%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International
Sales by segment of business
Sales to customers	$ 148	140	$ 458	419
Percent Change (as a percent)	5.50%		9.30%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI®
Sales by segment of business
Sales to customers	$ 260	210	$ 792	611
Percent Change (as a percent)	23.60%		29.60%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S.
Sales by segment of business
Sales to customers	$ 226	185	$ 692	536
Percent Change (as a percent)	22.40%		29.10%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International
Sales by segment of business
Sales to customers	$ 34	25	$ 100	75
Percent Change (as a percent)	32.30%		33.10%
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION
Sales by segment of business
Sales to customers	$ 97	96	$ 304	388
Percent Change (as a percent)	0.10%		(21.70%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | U.S.
Sales by segment of business
Sales to customers	$ 40	36	$ 121	179
Percent Change (as a percent)	11.50%		(32.30%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | International
Sales by segment of business
Sales to customers	$ 57	61	$ 183	210
Percent Change (as a percent)	(6.70%)		(12.70%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 1,281	1,316	$ 3,625	3,936
Percent Change (as a percent)	(2.60%)		(7.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 931	955	$ 2,574	2,804
Percent Change (as a percent)	(2.60%)		(8.20%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 351	360	$ 1,052	1,131
Percent Change (as a percent)	(2.70%)		(7.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO®
Sales by segment of business
Sales to customers	$ 630	613	$ 1,716	1,704
Percent Change (as a percent)	2.90%		0.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S.
Sales by segment of business
Sales to customers	$ 630	613	$ 1,716	1,704
Percent Change (as a percent)	2.90%		0.70%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET®
Sales by segment of business
Sales to customers	$ 224	179	$ 578	558
Percent Change (as a percent)	24.70%		3.60%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S.
Sales by segment of business
Sales to customers	$ 156	125	$ 405	411
Percent Change (as a percent)	24.70%		(1.60%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International
Sales by segment of business
Sales to customers	$ 68	55	$ 173	147
Percent Change (as a percent)	24.70%		18.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX®
Sales by segment of business
Sales to customers	$ 132	198	$ 423	607
Percent Change (as a percent)	(33.30%)		(30.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S.
Sales by segment of business
Sales to customers	$ 69	126	$ 215	387
Percent Change (as a percent)	(45.40%)		(44.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International
Sales by segment of business
Sales to customers	$ 63	72	$ 208	220
Percent Change (as a percent)	(12.20%)		(5.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION
Sales by segment of business
Sales to customers	$ 294	325	$ 908	$ 1,067
Percent Change (as a percent)	(9.50%)			(14.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | U.S.
Sales by segment of business
Sales to customers	$ 75	91	$ 238	$ 302
Percent Change (as a percent)	(17.90%)		(21.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | International
Sales by segment of business
Sales to customers	$ 219	234	$ 670	765
Percent Change (as a percent)	(6.20%)		(12.30%)
MEDICAL DEVICES
Sales by segment of business
Sales to customers	$ 6,150	6,383	$ 16,370	19,331
Percent Change (as a percent)	(3.60%)		(15.30%)
MEDICAL DEVICES | U.S.
Sales by segment of business
Sales to customers	$ 3,092	3,057	$ 7,852	9,249
Percent Change (as a percent)	1.20%		(15.10%)
MEDICAL DEVICES | International
Sales by segment of business
Sales to customers	$ 3,058	3,326	$ 8,518	10,082
Percent Change (as a percent)	(8.10%)		(15.50%)
MEDICAL DEVICES | Interventional Solutions
Sales by segment of business
Sales to customers	$ 836	741	$ 2,153	2,223
Percent Change (as a percent)	12.90%		(3.10%)
MEDICAL DEVICES | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 399	357	$ 1,019	1,066
Percent Change (as a percent)	11.80%		(4.40%)
MEDICAL DEVICES | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 437	382	$ 1,134	1,156
Percent Change (as a percent)	14.00%		(2.00%)
MEDICAL DEVICES | Orthopaedics
Sales by segment of business
Sales to customers	$ 2,083	2,138	$ 5,572	6,566
Percent Change (as a percent)	(2.60%)		(15.10%)
MEDICAL DEVICES | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 1,308	1,301	$ 3,427	3,950
Percent Change (as a percent)	0.60%		(13.20%)
MEDICAL DEVICES | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 774	837	$ 2,145	2,616
Percent Change (as a percent)	(7.50%)		(18.00%)
MEDICAL DEVICES | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 345	336	$ 908	1,061
Percent Change (as a percent)	2.40%		(14.50%)
MEDICAL DEVICES | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 221	204	$ 564	633
Percent Change (as a percent)	8.70%		(10.90%)
MEDICAL DEVICES | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 124	133	$ 344	428
Percent Change (as a percent)	(7.20%)		(19.80%)
MEDICAL DEVICES | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 308	344	$ 825	1,085
Percent Change (as a percent)	(10.90%)		(24.00%)
MEDICAL DEVICES | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 205	209	$ 527	650
Percent Change (as a percent)	(1.90%)		(19.00%)
MEDICAL DEVICES | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 102	136	$ 298	435
Percent Change (as a percent)	(24.80%)		(31.50%)
MEDICAL DEVICES | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 685	677	$ 1,892	2,034
Percent Change (as a percent)	1.30%		(7.00%)
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 433	415	$ 1,194	1,239
Percent Change (as a percent)	4.20%		(3.60%)
MEDICAL DEVICES | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 253	262	$ 698	795
Percent Change (as a percent)	(3.40%)		(12.20%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 745	778	$ 1,947	2,384
Percent Change (as a percent)	(4.30%)		(18.30%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 449	472	$ 1,142	1,427
Percent Change (as a percent)	(4.90%)		(20.00%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International
Sales by segment of business
Sales to customers	$ 295	306	$ 805	957
Percent Change (as a percent)	(3.40%)		(15.80%)
MEDICAL DEVICES | Surgery
Sales by segment of business
Sales to customers	$ 2,152	2,311	$ 5,803	7,059
Percent Change (as a percent)	(6.90%)		(17.80%)
MEDICAL DEVICES | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 913	940	$ 2,247	2,867
Percent Change (as a percent)	(3.00%)		(21.70%)
MEDICAL DEVICES | Surgery | International
Sales by segment of business
Sales to customers	$ 1,239	1,371	$ 3,556	4,192
Percent Change (as a percent)	(9.60%)		(15.20%)
MEDICAL DEVICES | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 1,000	1,010	$ 2,723	3,019
Percent Change (as a percent)	(1.10%)		(9.80%)
MEDICAL DEVICES | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 421	409	$ 1,079	1,209
Percent Change (as a percent)	3.00%		(10.70%)
MEDICAL DEVICES | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 579	602	$ 1,644	1,811
Percent Change (as a percent)	(3.90%)		(9.20%)
MEDICAL DEVICES | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 1,152	1,301	$ 3,080	4,040
Percent Change (as a percent)	(11.40%)		(23.80%)
MEDICAL DEVICES | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 492	531	$ 1,168	1,658
Percent Change (as a percent)	(7.60%)		(29.60%)
MEDICAL DEVICES | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 660	769	$ 1,912	2,381
Percent Change (as a percent)	(14.10%)		(19.70%)
MEDICAL DEVICES | Vision
Sales by segment of business
Sales to customers	$ 1,081	1,193	$ 2,843	3,483
Percent Change (as a percent)	(9.40%)		(18.40%)
MEDICAL DEVICES | Vision | U.S.
Sales by segment of business
Sales to customers	$ 473	459	$ 1,160	1,366
Percent Change (as a percent)	3.10%		(15.10%)
MEDICAL DEVICES | Vision | International
Sales by segment of business
Sales to customers	$ 608	734	$ 1,683	2,117
Percent Change (as a percent)	(17.20%)		(20.50%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 830	893	$ 2,198	2,559
Percent Change (as a percent)	(7.10%)		(14.10%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 375	339	$ 924	993
Percent Change (as a percent)	10.90%		(6.90%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 455	555	$ 1,274	1,566
Percent Change (as a percent)	(18.10%)		(18.70%)
MEDICAL DEVICES | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 251	299	$ 645	923
Percent Change (as a percent)	(16.30%)		(30.20%)
MEDICAL DEVICES | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 98	120	$ 236	373
Percent Change (as a percent)	(18.90%)		(36.80%)
MEDICAL DEVICES | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 153	$ 180	$ 409	$ 551
Percent Change (as a percent)	(14.60%)		(25.70%)

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	Apr. 01, 2019	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		1.70%		(2.00%)
Sales to customers		$ 21,082	$ 20,729	$ 60,109	$ 61,312
Percentage Change in Operating Income Loss				13.30%
Earnings before provision for taxes on income		4,401	1,647	$ 14,850	13,110
In-process research and development		138	0	144	890
Reversal of contingent consideration				1,148	0
Restructuring charges		68	69	187	162
Revenues from External Customers and Long-Lived Assets [Line Items]
Amount prepaid and due to manufacturers		800
Consumer Health*
Segment Reporting Information [Line Items]
Sales to customers		3,514	3,469	10,435	10,331
Restructuring charges				100	100
Litigation expense		500		1,200	200
Revenues from External Customers and Long-Lived Assets [Line Items]
Litigation expense		500		1,200	200
PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers		11,418	10,877	33,304	31,650
In-process research and development					900
Litigation expense		1,000	4,000	1,000	4,300
Research and Development Expense					300
Revenues from External Customers and Long-Lived Assets [Line Items]
Litigation expense		1,000	4,000	1,000	4,300
Medical Devices
Segment Reporting Information [Line Items]
Sales to customers		6,150	6,383	16,370	19,331
Restructuring charges		100	100	200	200
Litigation expense					300
Revenues from External Customers and Long-Lived Assets [Line Items]
Litigation expense					300
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income		4,640	1,823	$ 15,461	13,664
Percentage Change in Operating Income Loss				13.20%
Operating Segments | Consumer Health*
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 191	653	$ 993	1,800
Percentage Change in Operating Income Loss		(70.80%)		(44.80%)
Amortization		$ 100	100	$ 300	300
Operating Segments | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Total Segment Operating Income		3,439	(222)	11,787	5,786
Amortization		800	800	2,400	2,400
Restructuring charges				100	100
Unrealized Gain (Loss) on Securities			(100)	200	200
Acquisition Costs, Period Cost					100
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 1,010	1,392	$ 2,681	6,078
Percentage Change in Operating Income Loss		(27.40%)		(55.90%)
Amortization		$ 200	200	$ 700	700
In-process research and development		100		100
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 239	176	611	554
Ci:z Holdings Co. Ltd. | Consumer Health*
Segment Reporting Information [Line Items]
Gain on sale of equity investments					300
Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration				$ 1,148
United States
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		2.70%		0.00%
Sales to customers		$ 11,086	10,791	$ 31,324	31,323
United States | Consumer Health*
Segment Reporting Information [Line Items]
Sales to customers		1,556	1,394	4,853	4,369
United States | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers		6,438	6,340	18,619	17,705
United States | Medical Devices
Segment Reporting Information [Line Items]
Sales to customers		$ 3,092	3,057	$ 7,852	9,249
Europe
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		8.00%		(0.70%)
Sales to customers		$ 4,819	4,461	$ 13,709	13,803
Western Hemisphere, excluding U.S.
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(12.90%)		(11.60%)
Sales to customers		$ 1,296	1,488	$ 3,931	4,446
Asia-Pacific, Africa
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(2.70%)		(5.10%)
Sales to customers		$ 3,881	$ 3,989	$ 11,145	11,740
AdvancedSterilizationProducts
Segment Reporting Information [Line Items]
Gain from divestiture of business	$ 2,000
AdvancedSterilizationProducts | Medical Devices
Segment Reporting Information [Line Items]
Gain from divestiture of business					$ 2,000
Other Income | Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration				1,100
Other Income | Auris Health | Medical Devices
Segment Reporting Information [Line Items]
Reversal of contingent consideration		$ 200		$ 1,100

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Sales by geographic area
Sales	$ 21,082	$ 20,729	$ 60,109	$ 61,312
Percentage Change In Sales By Geographic Area	1.70%		(2.00%)
United States
Sales by geographic area
Sales	$ 11,086	10,791	$ 31,324	31,323
Percentage Change In Sales By Geographic Area	2.70%		0.00%
Europe
Sales by geographic area
Sales	$ 4,819	4,461	$ 13,709	13,803
Percentage Change In Sales By Geographic Area	8.00%		(0.70%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,296	1,488	$ 3,931	4,446
Percentage Change In Sales By Geographic Area	(12.90%)		(11.60%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,881	$ 3,989	$ 11,145	$ 11,740
Percentage Change In Sales By Geographic Area	(2.70%)		(5.10%)

Business Combinations and Div_2

Business Combinations and Divestitures - Narrative (Details) SFr / shares in Units, shares in Millions, SFr in Millions, $ in Millions, ¥ in Billions

Oct. 01, 2020USD ($)

Apr. 01, 2019USD ($)

Jan. 17, 2019USD ($)

Jan. 17, 2019JPY (¥)

Sep. 27, 2020USD ($)shares

Sep. 27, 2020CHF (SFr)shares

Mar. 29, 2020USD ($)

Sep. 29, 2019USD ($)

Mar. 31, 2019USD ($)

Sep. 27, 2020USD ($)

Sep. 29, 2019USD ($)

Sep. 27, 2020CHF (SFr)SFr / shares

Dec. 29, 2019USD ($)

Jan. 16, 2019

Business Acquisition [Line Items]

Goodwill

$ 34,307

$ 34,307

$ 33,639

Contingent consideration

636

636

$ 1,715

Reversal of contingent consideration

1,148

$ 0

Asset write-downs

198

1,019

Other (income) expense, net

(1,200)

$ (4,214)

(545)

$ (2,509)

bermekimab

Business Acquisition [Line Items]

Business acquisition cost

$ 800

Intangible assets

800

Verb Surgical Inc.

Business Acquisition [Line Items]

Intangible assets

400

Goodwill

200

Other assets

200

Liabilities assumed

300

Fair value of previously held equity investment

400

Auris Health

Business Acquisition [Line Items]

Business acquisition cost

$ 3,400

Intangible assets

3,000

Goodwill

2,000

Liabilities assumed

1,800

Contingent consideration

2,350

Marketable securities

200

Reversal of contingent consideration

1,148

Auris Health | Purchased In-Process Research And Development

Business Acquisition [Line Items]

Asset write-downs

100

Ci:z Holdings Co. Ltd.

Business Acquisition [Line Items]

Business acquisition cost

$ 2,100

¥ 230

Intangible assets

1,500

Goodwill

1,200

Liabilities assumed

400

Foreign exchange rate

109.06

Other (income) expense, net

$ 300

Adjustments made to intangible assets

$ 100

Weighted average useful life

15 years 3 months 18 days

Momenta [Member] | Subsequent Event

Business Acquisition [Line Items]

Business acquisition cost

$ 6,500

AdvancedSterilizationProducts

Business Acquisition [Line Items]

Gain from divestiture of business

2,000

Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain

Business Acquisition [Line Items]

Assets held for sale, current

$ 100

100

Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts

Business Acquisition [Line Items]

Disposal group consideration

2,800

Disposal group consideration, cash

2,700

Receivables retained

$ 100

Idorsia

Business Acquisition [Line Items]

Shares issued in transaction (in shares) | shares

11.8

11.8

Percentage ownership before transaction

8.30%

8.30%

Gross proceeds on sale

$ 357

SFr 337

Sales price per share (in CHF per share) | SFr / shares

SFr 28.55

Ownership interest after sale | shares

38.7

38.7

Percentage ownership after transaction

20.00%

20.00%

Idorsia | Convertible Debt | Idorsia

Business Acquisition [Line Items]

Long-term debt | SFr

SFr 445

Idorsia | Idorsia | Line of Credit | Revolving Credit Facility

Business Acquisition [Line Items]

Line of credit | SFr

SFr 243

Other Income | Auris Health

Business Acquisition [Line Items]

Reversal of contingent consideration

$ 1,100

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	1 Months Ended				3 Months Ended		9 Months Ended
	Jun. 28, 2020USD ($)	Apr. 30, 2020USD ($)	Jan. 31, 2020USD ($)	Jul. 31, 2018USD ($)	Mar. 29, 2020USD ($)	Dec. 29, 2019USD ($)claimant	Sep. 27, 2020USD ($)claimantpatient	Oct. 31, 2020USD ($)	Oct. 31, 2019USD ($)
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							600
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							8,200
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							15,400
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							10,400
XARELTO®
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							15,000
Talc
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							21,800
Invokana
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							300
Physiomesh
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants							4,000
Opioid
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants						3,100
Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $		$ 344	$ 344		$ 6.8	$ 8,000
Pending Litigation
Legal Proceeding (Textuals)
Loss Contingency, Estimate of Possible Loss | $									$ 4,000
Pending Litigation | Subsequent Event
Legal Proceeding (Textuals)
Loss Contingency, Estimate of Possible Loss | $								$ 5,000
Loss Contingency, Estimate of Additional Possible Loss | $								$ 1,000
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient							10,000
Baby Powder
Legal Proceeding (Textuals)
Previous damages awarded and revised | $				$ 4,700
Baby Powder | Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $	$ 2,100
Oklahoma Attorney General vs. Johnson & Johnson and JPI | settled litigation
Legal Proceeding (Textuals)
Damages awarded | $							$ 465
Oklahoma Attorney General vs. Johnson & Johnson and JPI | Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $							$ 572

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 68	$ 69	$ 187	$ 162
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	130		363
Restructuring charges recorded to date	1,200		1,200
Supply Chain | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	68		187
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	32		69
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	30		107
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	1,900		1,900
Cost savings expected	600		600
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	2,300		2,300
Cost savings expected	800		800
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges			363
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 100	$ 100	$ 200	$ 200
Medical Devices | Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Period for activity			4 years
Medical Devices | Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Period for activity			5 years

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2020	Sep. 29, 2019	Sep. 27, 2020	Sep. 29, 2019
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 68	$ 69	$ 187	$ 162
Period of cash outlays for severance expected to be paid out			2 years
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning			$ 180
Restructuring charges			363
Payments for Restructuring			(315)
Restructuring Reserve, Settled without Cash			(72)
Reserve balance ending	156		156
Medical Devices | Employee Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning			164
Restructuring charges			0
Payments for Restructuring			(18)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	146		146
Medical Devices | Asset Write-off
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			55
Payments for Restructuring			0
Restructuring Reserve, Settled without Cash			(55)
Reserve balance ending	0		0
Medical Devices | Other Restructuring
Restructuring Reserve [Roll Forward]
Reserve balance beginning			16
Restructuring charges			308
Payments for Restructuring			(297)
Restructuring Reserve, Settled without Cash			(17)
Reserve balance ending	$ 10		$ 10